 
 
RECOVER -NEURO: A Platform Protocol for Evaluation of 
Interventions for Cognitive Dysfunction in Post- Acute 
Sequelae of SARS- CoV-2 Infection  (PASC)  
 
National Clinical Trial (NCT) Identified Number   
[STUDY_ID_REMOVED]  
 
Co-Principal Investigator s 
 
David Knopman,  MD 
knopman@mayo.edu  
 Daniel Laskowitz, MD, MHS  
daniel.laskowitz@duke.edu  
 
Deborah Koltai, PhD  
attix001@duke.edu  
 Leigh Elkins Charvet, PhD  
leigh.charvet@nyulangone.org  
 
Juan Wisn ivesky, MD, DrPh  
juan.wisnivesky@mountsinai.org  
 Alex Federman, MD  
alex.federman@mountsinai.org  
 
Jacqueline H. Becker, PhD  
jacqueline.becker@mountsinai.org   
 
Protocol IND/IDE Sponsor   
Kanecia Zimmerman, MD , PhD, MPH  
 
Funded by : National Institutes of Health  
 
Version Number : v3.0 
Version Date: 10JAN202 4 

RECOVER -NEURO  CD_Protocol_V3.0_2024_01_10  
  
 ii Table of Contents  
List of Tables  ................................ ................................ ................................ ................................ ......... iv 
List of Figures ................................ ................................ ................................ ................................ ........  v 
STATEMENT OF COMPLIANCE ................................ ................................ ................................ ..........  1 
1.1 Synopsis  ................................ ................................ ................................ ............................... 1 
1.2 Schema ................................ ................................ ................................ ................................  2 
1.3 Key Roles  ................................ ................................ ................................ .............................  3 
2 INTRODUCTION ................................ ................................ ................................ .......................... 4 
2.1 Study Rationale ................................ ................................ ................................ ...................  4 
2.2 Background  ................................ ................................ ................................ .......................... 4 
2.3 Risk/Benefit Assessment  ................................ ................................ ................................ ... 5 
2.3.1 Known Potential Risks  ................................ ................................ ...................... 5 
2.3.2  Known Potential Benefits  ................................ ................................ .................. 6 
2.3.3  Assessment of Potential Risks and Benefits  ................................ .................  6 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ............................... 7 
4 STUDY DESIGN ................................ ................................ ................................ ...........................  8 
4.1 Overall Design ................................ ................................ ................................ .....................  8 
4.2 Scientific Rationale for Study Design  ................................ ................................ ............... 8 
4.3 Justification for Dose  ................................ ................................ ................................ ..........  9 
4.4 End of Study Definition  ................................ ................................ ................................ ....... 9 
5 STUDY POPULATION  ................................ ................................ ................................ .................  9 
5.1 Inclusion Criteria  ................................ ................................ ................................ .................. 9 
5.2 Exclusion Criteria  ................................ ................................ ................................ ..............  10 
5.3 Lifestyle Considerations  ................................ ................................ ................................ ... 11 
5.4 Screen Failures  ................................ ................................ ................................ .................  12 
5.5 Study Definition of Enrollment  ................................ ................................ .........................  12 
5.6 Strategies for Recruitment and Retention ................................ ................................ ...... 12 
6 STUDY INTERVENTION ................................ ................................ ................................ ........... 13 
6.1 Study Intervention(s) Administration ................................ ................................ ............... 13 
6.1.1  Study Intervention Description ................................ ................................ ....... 13 
6.1.2  Dosing and Administration ................................ ................................ .............  13 
6.2 Measures to Minimize Bias: Randomization and Blinding ................................ ........... 13 
6.2.1  Unblinding ................................ ................................ ................................ ......... 14 
6.3 Study Intervention Adherence  ................................ ................................ .........................  14 
6.4 Concomitant Therapy  ................................ ................................ ................................ ....... 14 
6.4.1  Prohibited Medications ................................ ................................ .................... 14 
6.4.2  Alternative Therapy  ................................ ................................ .........................  16 
6.4.3 Rescue Medicine ................................ ................................ .............................  16 
7 PARTICIPANT DISCONTINUATION/WITHDRAWAL  ................................ ...........................  16 
7.1 Participant Discontinuation from Intervention  ................................ ................................  16 
7.2 Participant Withdrawal from the Study  ................................ ................................ ........... 17 
7.3 Lost to Follow -Up ................................ ................................ ................................ ..............  17 
7.4 Study Halting Rules  ................................ ................................ ................................ ..........  17 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................ ....................................  18 
RECOVER -NEURO  CD_Protocol_V3.0_2024_01_10  
  
 iii 8.1 Schedule of Procedures  ................................ ................................ ................................ ... 18 
8.2 Screening (Day - 14 to 0)  ................................ ................................ ................................ .. 19 
8.3 Baseline (Day - 4 to 0)  ................................ ................................ ................................ ....... 19 
8.4 Start of Intervention (Day 0 + 21 days)  ................................ ................................ ..........  20 
8.5 Middle of Intervention (MOI ± 3 days)  ................................ ................................ ............ 20 
8.6 End of Intervention (EOI ± 3 days) ................................ ................................ .................. 20 
8.7 End of Study (EOI + 90 days ( ±3 days))  ................................ ................................ ........  21 
8.8 Clinical Laboratory Assessments  ................................ ................................ .................... 21 
8.9 Study Assessments ................................ ................................ ................................ ..........  21 
8.9.1  Everyday Cognition 2 (ECog2)  ................................ ................................ ...... 22 
8.9.2  PROMIS -Cog  ................................ ................................ ................................ ... 22 
8.9.3  Exploratory PROs  ................................ ................................ ............................ 22 
8.9.4  Neurocognitive Battery ................................ ................................ .................... 23 
8.10  Biorepository For Future Research  ................................ ................................ .................  25 
9 SAFETY ASSESSMENTS AND REPORTING  ................................ ................................ ....... 25 
9.1 Safety Events  ................................ ................................ ................................ .....................  25 
9.1.1  Definition of Safety Events  ................................ ................................ ............. 25 
9.1.2  Collection Period of AE and SAE Information..............................................  27 
9.1.3  Time Period and Frequency for Event Assessment and Follow -Up ......... 28 
9.1.4  Reporting and Monitoring of SAEs and UADEs  ................................ ..........  29 
9.1.5  Events of Special Interest  ................................ ................................ ............... 30 
9.1.6  Reporting of Pregnancy  ................................ ................................ .................. 30 
10 STATISTICAL CONSIDERATIONS  ................................ ................................ .........................  30 
10.1  General Considerations  ................................ ................................ ................................ .... 30 
10.2  Statistical Hypotheses  ................................ ................................ ................................ ...... 31 
10.3  Sample Size Determination ................................ ................................ .............................  31 
10.4  Populations for Analyses  ................................ ................................ ................................ .. 31 
10.5  Statistical Analyses  ................................ ................................ ................................ ........... 31 
10.5.1  Analysis of the Primary Endpoint  ................................ ................................ .. 31 
10.5.2  Analyses of the Secondary Endpoint(s)  ................................ .......................  32 
10.5.3  Analysis of the Exploratory Endpoint(s) ................................ ........................ 32 
10.5.4  Missing Data................................ ................................ ................................ ..... 32 
10.5.5  Planned Interim Analyses  ................................ ................................ ............... 32 
11 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ..............  33 
11.1  Regulatory, Ethical, and Study Oversight Considerations  ................................ ........... 33 
11.1.1  Informed Consent Process  ................................ ................................ .............  33 
11.1.2  Study Discontinuation and Closure  ................................ ............................... 34 
11.1.3  Confidentiality and Privacy  ................................ ................................ .............  34 
11.1.4  Key Roles and Study Governance  ................................ ................................  34 
11.1.5  Data and Safety Monitoring Board ................................ ................................  35 
11.1.6  Clinical Monitoring  ................................ ................................ ...........................  35 
11.1.7  Quality Assurance and Quality Control  ................................ .........................  35 
11.1.8  Data Handling and Record Keeping  ................................ .............................  36 
11.1.9  Protocol Deviations  ................................ ................................ .........................  36 
RECOVER -NEURO  CD_Protocol_V3.0_2024_01_10  
  
 iv 11.1.10  Publication and Data Sharing Policy  ................................ .............................  36 
11.1.11  Conflict of Interest Policy  ................................ ................................ ................ 37 
11.2  Abbreviations  ................................ ................................ ................................ .....................  37 
11.3  Proto col Amendment History  ................................ ................................ ...........................  38 
12 REFERENCES  ................................ ................................ ................................ ............................ 40 
13 APPENDIX A  ................................ ................................ ................................ ............................... 46 
13.1  Intervention Rationale ................................ ................................ ................................ ....... 46 
13.1.1  BrainHQ  ................................ ................................ ................................ ............ 46 
13.1.2  PASC -Cognitive Recovery  ................................ ................................ .............  46 
13.1.3  Transcranial Direct Current Stimulation ................................ ........................ 47 
13.2  Exclusion Criteria (Appendix Level)  ................................ ................................ ................ 47 
13.3  Study Design ................................ ................................ ................................ ...................... 47 
13.3.1  Design Rationale ................................ ................................ ............................. 48 
13.3.2  Randomization ................................ ................................ ................................ . 48 
13.3.3  Blinding  49 
13.3.4  Schema 49 
13.3.5  Control /Comparator  ................................ ................................ .........................  49 
13.4  Intervention Procedures  ................................ ................................ ................................ ... 49 
13.4.1  BrainHQ  ................................ ................................ ................................ ............  49 
13.4.2  PASC -Cognitive Recovery  ................................ ................................ ............. 50 
13.4.3  Transcranial Direct Current Stimulation ................................ ........................ 50 
13.4.4  Dosing  51 
13.4.5  Schedule of Procedures (Appendix -Level Differences)  .............................. 51 
13.4.6  Adherence  ................................ ................................ ................................ ........  52 
13.5  Safety  ................................ ................................ ................................ ................................ .. 52 
13.6  Events of Special Interest  ................................ ................................ ................................  52 
13.7  Pregnancy and Lifestyle Considerations  ................................ ................................ ........  52 
13.8  Statistical Considerations (Appendix Level)  ................................ ................................ .. 53 
13.8.1  Sample Size Determination ................................ ................................ ............  53 
13.8.2  Primary and Secondary Comparisons  ................................ .......................... 53 
 
List of Tables  
Table 1. Summary of study objectives, outcome measures, and endpoints  ................................ .... 7 
Table 2. Prohibited medications  ................................ ................................ ................................ ...........  15 
Table 3. Schedule of study procedures ................................ ................................ ............................... 18 
Table 4. Comparison studies for Appendix A  ................................ ................................ .....................  48 
Table 5. PASC -CoRE session content  ................................ ................................ ................................  50 
Table 6. Effect sizes that can be detected with 80% and 90% power under various scenarios for 
enrollment and loss to follow -up ................................ ................................ ................... 53 
  
 
RECOVER -NEURO  CD_Protocol_V3.0_2024_01_10  
  
 v List of Figures  
Figure 1. Overall protocol schema  ................................ ................................ ................................ ......... 2 
Figure 2. Schematic of Appendix A intervention ................................ ................................ ................ 49 
Figure 3. Equipment for tDCS intervention ................................ ................................ .........................  51 
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
1 STATEMENT OF COMPLIA NCE  
 
The trial will be carried out in accordance with International Conference on Harmonisation Good Clinical 
Practice ( ICH GCP) and the following :  
 
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812)  
 National Institutes of Health ( NIH)-funded investigators and clinical trial site  staff who are responsible 
for the conduct, management, or oversight of NIH -funded clinical trials have completed Human Subjects 
Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be 
submitted to the central Institutional Review Board ( IRB) for review and approval . Approval of both the 
protocol and the consent form (s) must be obtained before any participant is enrolled. Any amendment 
to the protocol will require review and approval by the IRB before the changes are implemented to the study. In addition, all changes to the consent form will be IRB -approved; a determination will be made 
regarding whether  a new consent needs to be obtained from participants  who provided consent , using a 
previously approved consent form . 
 
1.1 SYNOPSIS  
 
Title:  RECOVER -NEURO: A Platform Protocol for Evaluation of Interventions for 
Cognitive Dysfunction in Post -Acute Sequelae of SARS -CoV-2 Infection (PASC)  
Study Description:  This platform protocol is designed to be flexible so that it is suitable for a 
wide range of settings within health care systems, for remote settings , and in 
community settings where it can be integrated into COVID -19 programs and 
subsequent treatment plans.  
 
This protocol is a prospective, multi -center, multi -arm, randomized, 
controlled platform trial evaluating potential interventions  for symptoms of 
cognitive dysfunction that emerge in patients with PASC . The hypothesis is 
that PASC -associated  dysfunction in cognitive domains, such as executive 
function and attention, may be improved by interventions  that selectively 
focus on enhancing tho se domains.  
Objectives:    Primary:  
1. Evaluate the intervention’s effect on  self-reported  cognitive function 
versus comparator  
Secondary:  
1. Assess the intervention’s effect on cognitive patient -reported 
outcomes (PROs) versus comparator   
2. Compare the intervention’s effect on a n objective  neurocognitive 
battery versus comparator  
3. Evaluate the intervention’s durable effect on  self-reported  cognitive 
function versus comparator  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
2 4. Characterize the intervention’s safety  
Exploratory:   
1. Assess the intervention’s effect on exploratory PROs  versus 
comparator   
Study Population:  Adults self -reporting cognitive dysfunction at least 12 weeks after a SARS -
Cov-2 infection. 
  
The goal is to have a diverse population, including underserved communities  
and racial/ethnic populations frequently underrepresented in clinical 
research .  
Phase:  Phase 2b  
Description of 
Sites/Facilities 
Enrolling Participants:  Participants  will be recruited from various acute COVID -19 trials and existing 
RECOVER initiatives including, but not limited to , the longitudinal cohort as 
well as other sites and research communities. Up to  45 sites in the US  may  
participate.  Though, the number and location of sites may differ among 
intervention appendices.  
Description of Study 
Intervention:  Each intervention  (fully described in each appendix ) represents a different 
conceptual approach and control. In general, interventions will target 
enhancement of cognitive domains that present  dysfunction following SARS -
CoV-2 infection.  
Participant Duration:  Participant duration will depend on the specific intervention  appendix . After 
the intervention, p articipants will have one follow -up visit at  90 days .  
  
1.2 SCHEMA  
Figure 1. Overall protocol schema 
 
Abbreviations: MOI, Middle of Intervention; EOI, End of Intervention; EOS, End of Study  
 
    

RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
3 1.3 KEY ROLES  
 
Platform  Protocol IND Sponsor :  
Kanecia Zimmerman, MD , PhD  
Duke Clinical Research Institute  
E-mail: kanecia.zimmerman@ duke.edu   
Phone: 919 -668- 8651    
Platform Protocol Co-Chairs and Co-Principal Investigator s: 
David Knopman, MD  
Mayo Clinic  
Email: knopman@mayo.edu  
Phone: 507 -266- 4106  
 
Daniel Laskowitz, MD, MHS  
Duke Clinical Research Institute  
E-mail: daniel.laskowitz@duke.edu  
Phone: 919 -684- 0056  Deborah Koltai, PhD  
Duke University Medical Center  
Email: attix001@duke.edu  
Phone: 919 -668- 2846  
Appendix A Co -Principal Investigator s: 
Leigh Elkins Charvet, PhD  
NYU Langone Health  
leigh .charvet@nyulangone.org  
 
Juan Wisni vesky, MD, DrPh  
Icahn School of Medicine at Mount Sinai  
juan.wisnivesky@mountsinai.org  
  Jacqueline H. Becker, Ph D 
Icahn School of Medicine at Mount Sinai  
jacqueline.becker@mountsinai.org  
 Alex Federman, MD  
Icahn School of Medicine at  Mount Sinai  
alex.federman@mountsinai.org   Appendix A Collaborator:  
Henry Mahncke, PhD  
Posit Science  
henry.mahncke@positscience.com  
 
  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
4 2  INTRODUCTION  
 
2.1 STUDY R ATIONALE  
Post- Acute Sequelae of SARS -CoV-2 infection (PASC), also known as Long COVID, is a chronic condition 
present in up to 80% of SARS -CoV-2-infected, hospitalized patients and 40% to 70% of non- hospitalized 
patients with COVID -19.1-4 The number of PASC patients is escalating, and the personal and global 
impact of these long- term symptoms from SARS -CoV-2 infection can be debilitating. A prominent PASC 
symptom is cognitive dysfunction,5 which can prevent patients’ return to work.6 Therefore, with the 
increasing number of people infected with SARS -CoV-2, an urgent and unmet clinical need exists to 
better understand the pathophysiology of PASC and to develop targeted interventions that restore 
patients’ cognitive function. This platform  protocol aims to investigate  interventions with prior evidence 
of improving cognitive function. If successful, results will enable providers to treat PASC -related  
cognitive dysfunction.   
2.2 BACKGROUND  
In 2019, a novel coronavirus -disease (COVID -19) emerged in Wuhan, China. A month later , the Chinese 
Center for Disease Control and Prevention identified a new beta -coronavirus ( severe acute respiratory 
syndrome  coronavirus 2, or SARS -CoV-2) as the etiological agen t.7 The clinical manifestations of COVID -
19 range from asymptomatic infection or mild, transient symptoms to severe viral pneumonia with respiratory failure , and other serious, life -threatening complications .  
COVID -19 has led to the death of more than 6 million people worldwide; however, this disease has 
affected  even more lives throu gh often- debilitating symptoms lingering long after acute SARS -CoV-2 
infection. Post -Acute Sequelae of SARS -CoV-2 infection  affects nearly every organ system, with more 
than 200 individual symptoms, ranging from new -onset anxiety, depression, and cognitive  difficulties  to 
shortness of breath, dizziness, and arrhythmia s.
6 Moreover, PASC can occur regardless  of severity of 
acute COVID -19 disease, and it impacts across socioeconomic, racial and ethnic, and age strata. These 
prolonged symptoms  open the door for substantial short - and long- term individual and societal costs , 
including healthcare costs and inability to work. Prolonged symptoms have kept individuals out of work, 
which has exacerbated poverty in the underserved, historically minoritized populations and worsened  a 
decades -long mental health crisis. Consider ing these costs, identification of safe and effective methods 
to treat and prevent the occurrence of PASC represents an urgent, unmet public health need.  
To address this need, the  NIH has launched the RECOVER initiative across the nation (RECOVER: 
Researching COVID to Enhance Recovery) to better understand the disease . The RECOVER Initiative 
brings together patients, caregivers, clinicians, community leaders, and scientists from across the nation 
to understand, prevent, and treat PASC. The RECOVER Consortium represents and supports researchers who are leading studies on PASC  at more than 200 sites  around the country. These studies have a 
diverse group of participants, including adults, pregnant women , and children.  Data from the RECOVER 
initiative , as well as existing literature , highlight cognitive dysfunction as a frequently reported symptom 
that is substantial ly importan t to patients. Additionally , patients with PASC -related  cognitive dysfunction 
express marked  heterogeneity in symptomology and presentation.
8,9  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
5 How COVID -19 induces cognitive dysfunction is not known. Postulated underlying mechanisms include  
neuro inflamm ation,10,11 loss of hippocampal neurons ,10 microglial dysfunction,11 and neuronal 
mitochondrial dysfunction.11 What is known is that, in otherwise healthy adults , symptoms  in the 
neuropsychiatric system cluster include persisting central fatigue,12-14 central sensitization 15(myalgia,16 
headache17), emotional dysregulation18,19 (depression,20-22 anxiety23,24), and  cognitive dysfunction (“brain 
fog”).5,25 Moreover, this cognitive dysfunction appears to persist for at least 7 to 12 months after acute 
SARS -CoV-2 infection.26,27 This long- lasting impact contributes to functional disability, poor quality of life, 
and psychological morbidity.28-31 This platform  protocol focuses on treating PASC -mediated cognitive 
dysfunction.  
No trials studying interventions directly addressing PASC -related  cognitive dysfunction have reported 
results. One study intervening with olfactory training for olfactory dysfunction in PASC patients did 
observe memory improvements,32 supporting  the hypothesis that elements of cognitive dysfunction are  
reversible.  
Furthermore, objective and subjective measures evaluating cognition in a PASC population are not well 
characterized. Objective measure s are preferred for analyzing treatment effects on cognition; however, 
per t he RECOVER initiative , only a portion of patients reporting cognitive problems truly have objective 
dysfunction through assessment. Therefore, to capture patients with objective deficits and those who 
do not but are still suffering in daily life with cognitive dysfunction, this platform  protocol will use a 
subjective measure, the Everyday Cognition 2 (ECog2),  to evaluate the interventions’ effects on 
cognitive dysfunction (see Section 4.2 for detail).  
The absence of data , heterogeneity and nove lty of PASC, discordance between reported symptoms and 
objective findings ,8,9,33 and lack of v alidated measures and endpoints specific to this disease process 
highlight the importance of studying interventions  in the context of well -controlled clinical trials  to 
ensure that optimal and appropriate therapies are made rapidly available for patients . Additionally, 
clinical trials performed  in the PASC population will test the utility of endpoints and outcome measures 
previously well-established in other disease processes .  
2.3 RISK/BENEFIT ASSESSM ENT  
 
2.3.1  KNOWN  POTENTIAL RISKS  
Potential risks of this trial  include those associated with the specific intervention  (refer to appendices for 
details), blood draws,  nasal swabs , and loss of confidentiality.  
Risks associated with blood draws include momentary discomfort and/or bruising. Infection, excess 
bleeding, clotting, or fainting are also possible, although unlikely. 
Risks associated with nasal swabs include mild irritation, insignificant local pain, and minor bleeding. 
Loss of confidentiality  is a risk . However, coding all participant data with a unique identification number 
will minimize this risk .  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
6 Participation in this study may induce post ex ertional malaise (PEM) in those  prone to PEM  or worsen 
symptoms in those who already have PEM. PEM may be triggered by travel to appointments, extended 
neurocognitive testing, or active participation in the interventions.   
2.3.2  KNOWN POTENTIAL BENE FITS 
Participants may  benefit directly from improved cognitive function.  
Future individuals who acquire PASC -mediated cognitive dysfunction will benefit from knowing effective 
treatment options.   
2.3.3  ASSESSMENT OF POTENT IAL RISKS AND BENEFITS  
Potential benefits may outweigh potential risks. Post -acute sequelae of SARS -CoV-2 infection  (PASC)  is a 
significant health issue and can have consequences that impact quality of life. These consequences are extremely important for the individual and the society at large.  
PEM will be assessed at multiple time points of the interventions.  
  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
7 3 OBJECTIVES AND ENDPO INTS  
The objectives, outcome measures, and endpoints for the trial are listed in Table 1. Further details on 
outcome measures and endpoints are provided in Section 10 and t he Statistical Analysis Plan (SAP).  
Table 1. Summary of study objectives, outcome measures, and endpoints  
OBJECTIVES  OUTCOME MEASURES  ENDPOINTS  
Primary    
Evaluate the intervention’s effect on 
self-reported cognitive function 
versus comparator  Everyday Cognition 2 (ECog2)  Change in average score 
from baseline to End of 
Intervention (EOI)  
Secondary    
Assess the intervention’s effect on 
cognitive patient -reported outcomes 
(PROs) versus comparator  PROMIS -cognitive function – short form 
8a (PROMIS -Cog) Change in total score from 
baseline to EOI and End of 
Study (EOS), defined as 90 days post -intervention  
Compare  the intervention’s effect on 
an objective neurocognitive battery versus comparator  • Audit ory Verbal Learning Test s 
• Symbol Digit Modalities Test  
• Verbal Fluency (lexical + semantic)  
• Digit Vigilance Test  
• Cogstate tests: Detection, Identification, One Back  
• NIH Toolbox Flanker Inhibitory Control and Attention Test  Change from baseline to 
EOI and EOS 
Evaluate the intervention’s durable 
effect on self-reported  cognitive 
function versus comparator  ECog2  Change  in average score  
from baseline to EOS  
Characterize the intervention’s safety  Serious Adverse Events  (SAEs) , 
Unanticipated Adverse Device Effects (UADEs),  and/or Events of Special 
Interest  (ESIs)  Proportion  of SAEs , 
UADEs,  and/or  ESIs 
Exploratory    
Assess the intervention ’s effect on 
exploratory  PROs  versus comparator  • PASC Symptom Questionnaire  
• Patient -reported Outcomes 
Measurement Information System 
(PROMIS)- 29+2  
• PROMIS -fatigue – short form 10 a 
(PROMIS -Fatigue)  
• PROMIS -8a sleep related impairment 
(PROMIS -SRI) 
• PROMIS -8b sleep disturbance 
(PROMIS -SD) 
• Modified DePaul Symptom Questionnaire Post Exertional Malaise (DSQ -PEM)  Change in tot al score from 
baseline to EOI and EOS  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
8  
4 STUDY DESIGN  
 
4.1 OVERALL  DESIGN  
The overall design is a platform protocol designed to be flexible so that it is suitable for a wide range of 
settings within healthcare systems , for remote settings,  and in community settings , where it can be 
integrated into COVID -19 testing programs and subsequent treatment plans. This platform protocol is a 
prospective, multi -center, multi -arm, randomized, controlled trial evaluating treatment of PASC -
mediated cogni tive dysfunction in outpatients previously infected with SARS -CoV-2. 
This protocol will recruit adults experiencing PASC symptoms for at least 12 weeks and reporting 
reduced cognitive function following acute COVID -19 infection. This protocol will enroll participants 
meeting patient reported outcome criteria for cognitive d ysfunction. Participants will consent before 
being randomly assigned to one of the actively enrolling interventions.  
Each appendix will describe a n intervention  that is sized to meet the platform  protocol objectives. 
Participants will be randomized to one  of the intervention  appendices that are actively enrolling at the 
time of randomization. See Section 6.2 for randomization details. Intervention  appendices may be 
added or removed according to adaptive design and/or emerging evidence. Various interventions  will be 
studied; refer to the protocol a ppendices for further information on each intervention .  
This protocol will leverage common data elements  (CDEs) already collected as part of the RECOVER 
initiative  as well as assess overall global health status and symptomatology. O rgan -specific assessment s, 
including PROs  of symptoms and functional status , and objective assessments  will also be done. 
Interv ention duration will be specific to an intervention appendix, but all will include a final study 
assessment 90 days after the intervention. F ollow -up will be a combination of in -person  visits when 
necessary to obtain objective clinical assessments and phone calls to be mindful of the participant 
burden.  
4.2 SCIENTIFIC RATIONALE FOR S TUDY DESIGN  
Each intervention  appendix under this platform  protocol will follow a  randomized trial design to 
compare the intervention (s) to a comparator . Intervention  appendice s will target affected cognitive 
domains, such as executive functioning and attention. A dditional interventions  can be studied as new 
interventions are available or as knowledge  of PASC -mediated cognitive dysfunction evolves . 
Inclusion will be based on pat ient-reported complaints (PROMIS -Cog) to maximize inclusiveness, 
because over half of individuals in the RECOVER observational study who had cognitive complaints do 
not have objective evidence of cognitive dysfunction. The RECOVER -NEURO Working Group recognizes 
the concern that those participants without objective evidence of cognitive dysfunction may be 
phenotypically different from those with objective cognitive dysfunction. However, while this is an issue 
for the FDA, FDA approval is not a goal here.  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
9 The primary outcome for this study uses a subjective assessment for cognitive function, the ECog2, 
instead of or without the addition of an objective assessment for multiple reasons: (a) the inclusion 
criteria do not require  objective criteria; (b) the sensi tivity of standard cognitive tests for PASC -related  
cognitive dysfunction is unknown; and (c) the cognitive deficits of the population under study are still 
undefined.  
Moreover, the original ECog was designed to measure specific aspects of everyday cognit ion related to 
memory, language, visuospatial functions, and executive functioning. The ECog2 is clinically relevant and 
has been validated in the setting of mild cognitive dysfunction, which may increase its sensitivity to the 
PASC population and to tracking functional outcomes longitudinally. Furthermore, t he ECog2 is a robust 
measure of perceived cognition, spanning across cognitive domains, unlike the other PROs being used. 
Finally, it has been translated into several languages and validated in a wide range of ethnic/racial 
minority populations and across educational levels, which increased the likelihood of generalizability.   
4.3 JUSTIFICATION FOR DO SE 
The dose and duration of the intervention  will be based on the specific intervention . Refer to the 
appendices  for details .  
4.4 END OF STUDY DEFINIT ION  
The End of S tudy will occur when all participants have completed their End of Study Visit .  
 
5 STUDY POPULATION  
 
5.1 INCLUSION CRITERIA  
In order to be eligible to participate in this study, an individual must meet all of the following criteria:  
1. ≥ 18 years of age at the time of enrollment  
2. PROMIS -Cog T -score < 40  
3. Previous suspected, probable, or confirmed SARS -CoV-2 infection, as defined by the Pan 
American Health Organization34 
Suspected case of SARS -CoV-2 infection - three options, A through C:  
A. Met clinical OR epidemiological criteria:  
a. Clinical criteria: Acute onset of fever AND cough (influenza- like illness) OR Acute 
onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, 
gener al, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, 
nausea, diarrhea, anorexia;  
b. Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID -19 cluster;  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
10 B. Present ed acute respiratory infection with history of fev er or measured fever of ≥ 38°C 
and cough, with onset within the last 10 days, and who requires hospitalization; or  
C. Present ed with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a 
positive professional use or self -test SARS -CoV-2 Ant igen- Rapid Diagnostic Test.  
Probable case of SARS -CoV-2 infection, defined as having met  clinical criteria above AND was  a 
contact of a probable or confirmed case or was  linked to a COVID -19 cluster.  
Confirmed case of SARS -CoV-2 infection - two options, A through B:  
A. Present ed with a positive nucleic acid amplification test, regardless of clinical criteria OR 
epidemiological criteria; or  
B. Met clinical AND/OR epidemiological criteria (See suspected case A), with a positive 
professional use or self -test SARS -CoV-2 Antigen- Rapid Diagnostic Test.  
* Suspected and probable cases will only be allowed if they occurred before May 1,  2021, and will be 
limited to 10 % of the study population. Otherwise, confirmed cases are required. 
4. Cognitive dysfunction symptoms following a SARS -CoV-2 infection th at have persisted for at 
least 12  weeks and are still present at the time of consent35,◊ 
5. Fluent in English or Spanish language  
6. Willing and able to provide informed consent, complete the intervention, complete the 
intervention assessments, and return for all of the necessary follow -up visits  
 
5.2 EXCLUSION CRITERIA  
An individual who meets any of the following criteria will be excluded from participation in this study:  
1. Prior or active unstable or progressive major psychiatric or neurologic condition that would not 
show improvement and could hide treatment effect , at the investigator’s discretion, including, but not limited to, the following examples:  
a. Progressive neurodegenerative disease, such as Alzheimer’s disease, Parkinson’s disease, etc.  
b. Past traumatic brain injury occurrence still associated with active post -concussive 
symptoms  
c. Uncontrolled seizure disorder, such as having at least one seizure in the last year that is adjudicated by clinical judgment  
d. Post-stroke deficits that may interfere with assessment, such as language  or 
communication difficulties, aphasia, etc.  
e. Formal thought disorders, such as schizophrenia, etc.   
f. Any neuropsychiatric or neurologic disorder uncontrolled for the previous six months  or 
that may interfere with assessment, at discretion of the investigator  
2. Known prior diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome, not related to SARS -CoV-2 infection  
3. Known active acute SARS -CoV-2 infection ≤ 4 weeks from consent  
4. Curren t use of medications listed in Table 2* 
5. History of electroconvulsive therapy  
6. Current use of any medication for treating PASC -related symptoms 
7. Attention -deficit/hyperactivity disorder ( ADHD) diagnosis following the onset of PASC ** 
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
11 8. Current diagnosis of alcohol and substance use disorders  
a. Prior use disorders acceptable if abstinence achieved and maintained for at least 12 
months before study enrol lment  
9. Insufficient visual, auditory, and motor function to participate in intervention and assessments  
10. Known pregnancy  
11. Current or recent use (within the last 2 months) of the intervention* **  
12. Known allergy/sensitivity/hypersensitivity to components of the intervention or comparator *** 
13. Currently receiving/using intervention from another clinical trial, such as another RECOVER 
trial****  
14. Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study  
a. The site investigator has the discretion to determine whether a participant is too 
cognitively impaired to participate and should instead be referred for clinical evaluation. 
* Participants who are currently taking  prohibited medications ( Table 2) or alternative therapies 
(Table 2, Section 6.4.2) may  undergo a 30-day washout period, which will be  determined by the 
site p rincipal investigator based on standard of care practices. However, if the site principal 
investigator determines that the participants must continue taking their current medication 
regimens  or alternative therapies, then the participants will be ineligible for enrollment .  
**Participants diagnosed with ADHD prior to PASC -related symptoms and who are compliant on 
stable doses of medication may participate per the investigator ’s discretion. Participants should 
agree to maintain a stable dose of their  medication while in the trial.   
*** Relevant if only one intervention appendix is open at the time of enrollment, though exclusion 
may be qualified in the appendix. If multiple intervention appendices are open, a participant may be excluded from any intervention appendix based on contraindications listed in the intervention appendix, current use of intervention, or known allergy/sens itivity/hypersensitivity and still remain 
eligible for the remaining intervention appendices.  
****Following another interventional trial’s end- of-study visit, participants must wait 90 days before 
enrolling into NEURO.   
Exclusions specific to intervention  appendices are listed in each appendix.  
5.3 LIFESTYLE CONSIDERAT IONS  
Participants must agree not to begin, resume, or increase the dose of any form of cognitive training or 
cognitive -enhancing supplement s until the end of the active intervention phase of the trial . Participants 
who stop taking a cognitive -enhancing supplement before being enrolled must complete 30 days of 
washout before beginning study procedures. Cognitive training is any non- pharmacological intervention 
that participants started intending to  enhance their cognition. A cognitive -enhancing supplement is any 
non- prescription compound being taken by participants with the goal of enhancing their cognition. 
Beginning, resuming, or increasing the dose of cognitive training or cognitive -enhancing supplements 
will result in a protocol deviation.  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
12 Participants  must agree not to change their current dose of stimulant , atypical stimulant, non- stimulant 
medication used to treat ADHD, or antidepressant medication while on- study, unless directed by their 
prescribing clinician, in which case the dose change will be recorded on the eCRF.  
 
Participants  capable of becoming pregnant  are encouraged  to use an effective method of contraception 
during study intervention administration and for at least 7 days after the final administration of study 
intervention. If this consideration is not required for a specific appendix, the appendix will expressly 
state that contraception is not required. Additionally, the appendix will state whether participant s can 
remain in the study if they  becomes pregnant.  
5.4 SCREEN FAILURES  
Screen failures are defined as participants who consent to participate in the clinical trial but are not 
subsequently randomly assigned to the study intervention or entered in the study. A minimal set of 
screen failure information is required to ensure transparent reporting of screen failure participants , to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements , and to 
respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, and eligibility criteria.   
5.5 STUDY DEFINITION OF ENROLLMENT  
For this study, enrollment is defined as signing consent  and completing randomization.  
5.6 STRATEGIES FOR RECRU ITMENT AND RETENTION  
The RECOVER Clinical Trial Data Coordinating Center (CT -DCC) will use an integrated strategy of 
coordinating with community organizations, the public, and clinical trial sites to identify and retain study 
participants. To ensure a diverse population is enrolled , strategies from prior successful initiatives will be 
refined and utilized. The study team will develop a comprehensive communication strategy involving 
print and social media, as well as leveraging existing organizational structures where possible, to educ ate the public on concerns about PASC and opportunities for clinical trial participation. Interested 
members of the public will be provided with information to contact a local site for potential participation .  
Participants can be recruited and identified through outreach by participating site s. Site investigators, or 
their designee s, may contact eligible participants to introduce the study and discuss study participation.  
Participants  may be recruited from other ongoing COVID -19 trials if they opted- in to  be contacted about 
future research opportunities. However, after completing other trials’ interventions, including other RECOVER trials, 90 days must lapse before screening for this trial.  
Finally, to support participant referral to actively enrolling tri als, a series of invitation algorithms based 
on appendix -specific inclusion/exc lusion criteria and participant -entered data may be used. Automatic 
invitations will be generated for participants who appear eligible based on trial interest, demographics, and medical history. Once participants accept the invitation and adequate consent is obtained, their 
information will be shared with the applicable study team .   
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
13 Patient advocates who  represent a diverse PASC community will be engaged in the study at every step. 
Patient advocates will serve as consultants to inform study design, protocol development, and 
recruitment and retention strategies.  
During the active study  period , study sites  will maintain close connections with study participants.  
 
6 STUDY INTERVENTION  
 
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
 
6.1.1  STUDY INTERVENTION  DESCRIPTION  
See appendices  for full descriptions . 
6.1.2  DOSING AND ADMINISTR ATION  
See appendices  for detailed description .  
6.2 MEASURES TO MINIMIZE  BIAS: RANDOMIZATION  AND BLINDING  
Since the form  of each intervention  may differ, the comparator s also may differ. In general, the 
comparator will be a reference intervention  against which the effectiveness or safety of an  experimental 
intervention is assessed. To achieve blinding and an equitable randomization probability, a two -step 
randomization process will be used.  The study will employ a simple (unstratified) randomization 
scheme.  
At the first stage, each participant will be assigned with equal probability to one of the intervention 
appendices for which the participant is eligible, after applying any intervention- specific safety 
exclusions. At the second stage, each participant will be assigned according to the specific appendix’s 
randomization procedure.  
If open intervention appendices have the ability to pool comparator s, randomization to either an 
intervention or comparator  will occur at an m:1 ratio, where m equals  the number of interventions 
currently active in the platform  protocol and which the participant is eligible to receive. For example, if 3 
interventions are active simultaneously with comparator s that can be pooled, and if the participant 
meets the criteria to receive all 3 interventions, the allocation ratio at the first step will be 1:1:1 and the 
second step 3:1 (intervention vs comparator) for an overall randomization ratio of 1:1:1:1. If 3 
interventions are available, but a participant is only eligible to receive 2 of the m, the allocation ratio at 
the first step will be 1:1, and at the second step will be 2:1 (intervention vs comparator ) for an overall 
randomization of 1:1:1. Inclusion of a comparator for each intervention enables masking of study 
participants and clinical  personnel to intervention  assignment at the second stage. Participants 
randomized to the control comparator will only be included in the analyses of the appendices for which 
they were eligible.  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
14 Participants assigned to comparator  will be considered part of pooled analyses if the intervention was 
active at the time of their enrollment and they were eligible to receive that intervention. This will result 
in approximately a 1:1 allocation ratio for any intervention to pooled comparator . If comparators differ 
substantially, the comparators will not be pooled.  
Sites will be informed to which intervention appendix participants are randomized, but, when 
applicable, not whether they are allocated to the active intervention arm or comparator  arm within that 
appendi x. The participants and investigators will be blinded throughout the study, when possible.  
If open intervention appendices do not have the ability to pool comparator s but have independent 
comparator s, at the second stage participants will be randomized in a 1:1 ratio to intervention vs 
comparator  inside the specific intervention appendix they were randomized to at the first stage of the 
randomization procedure.  
6.2.1  UNBLINDING  
The participant s, treating clinicians, and study personnel will remain blinded to intervention  versus 
comparator  assignment , when possible,  until after the database is locked and final  analysis is completed. 
Only the biostatistical team preparing closed interim reports will be unblinded. Unblinding will occur only if required for partic ipant safety or treatment, at the request of the treating clinician. Refer to the 
Manual of Procedures ( MOP) for further details.  
6.3 STUDY INTERVENTION  ADHERENCE 
Participants will be notified of the importance of adhering to the entire protocol . Adherence def initions 
and aids may be detailed  in each appendix.  
6.4 CONCOMITANT THERAPY  
For this protocol, a prescription medication is defined as a medication that can be prescribed only by a 
properly authorized/licensed clinician. M edications to be reported in the Case  Report Form ( CRF) are 
relevant concomitant prescription medications, over -the-counter medications , and supplements . 
Baseline concomitant medications will include all concomitant therapies taken by the participant within 
14 days of informed consent.  
Categorized as concomitant therapies for this protocol are forms of cognitive training and cognitive -
enhancing supplements, both of which are defined in Section 5.3. 
6.4.1  PROHIBITED MEDICATIO NS 
Any medication used for symptomatic treatment of PASC is not permitted during the study.  
Table 2 displays medications and therapies and their conditions for being allowed or prohibited for 
participation. If participants are on prohibited medications and interested in participating, they should 
be encouraged to discuss discontinuing medications with their clinicians. Additionall y, Table 2 lists  
commonly encountered medication examples . Questions about the status of other medications 
presenting in these drug classes should be directed to the sponsor.  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
15 Table 2. Prohibited medications and therapies  
 
  Drug class/Therapy Generic name
(examples)Brand name
(examples)Allowed Prohibited No tes
methylphenidateAdhansia, Aptensio, Concerta, 
Cotempla, Daytrana, Jornay, 
Focalin, Metadate, Methylin, 
Quillichew, Quillivant, Relexxii, 
Rit
alin
amphetamine/
dextroamphetamine/
lisdexamphetamineAdderall, Adzenys, Desoxyn, 
Dyanavel, Mydayis, Vyvanse
armodafinil Nuvigil
modafinil Provigil
bupropionAplenzin, Budeprion, Buproban, 
Forfivo, Wellbutrin, Zyban
amantadine Gocovri, Osmolex, SymmetrelParticipants who were on 
stable doses of atypical 
stimulants used for ADHD 
before  their PASC 
s
ymptoms will not need to 
washout, can maintain their current dose regimen.
All other instances of 
atypical stimulant use after a 30-day washout before randomizationAtypical stimulantDose should be stable ≥ 90 
days before randomization and 
maintained for study duration. A necessary change in dose does not
 cause discontinuation, but 
the dose change must be documented in the EDC.All other instances of 
stimulant useParticipants who were on 
stable doses of stimulants 
used for ADHD before th 
eir PASC symptoms will 
not need to washout, can maintain their current 
dose regimen
All other instances of 
stimulant use after a 30-day washout before randomization
Dose should be stable ≥ 90 
days before randomization and 
maintained for study duration.All other instances of 
atypical stimulant useStimulant
atomoxetine Strattera
viloxazine Qelbree
clonidine Catapres, Kapvay, Nexiclon
guanfacine Intuniv, Tenex
donepezil Aricept
memantine Namenda
rivastigmine Exelon
galantamine Razadyne
hydromorphone Dilaudid
methadone Dolophine, Methadose
meperidine Demerol, Meperitab
oxycodoneDazidox, Oxaydo, OxyCONTIN, 
Oxydose, Oxyfast, Roxicodone, Roxybond, Xtampza, Endodan, Percodan, Combunox, Endocet, Magnacet, Narvox, Percocet, Perloxx, Primalev, Roxicet, Roxilox, Tylox, Xartemix, Xolox
fentanylLazanda, Duragesic, Ionsys, 
Sublimaze
morphine
opiumcodeinehydrocodoneuse must be refrained within 48 
hours prior to assessments; failure to refrain will require rescheduling of the assessments. All other instances of 
narcotic use are exclusionary, such as higher frequency and doseOccasional use (1-2 
times/week) of low-dose narcotics according to local standards.
All other instances of 
narcotic use after a 30-day washout before randomizationDose should be stable ≥ 90 
days before randomization and maintained for study duration.Participants on non-
stimulant medications used to treat ADHD if the dose is not  stable 
or if the ADHD occurred after  the 
onset of PASCParticipants who were on 
stable doses of non-stimulant medications used for ADHD before their PASC symptoms will 
not need to washout, can 
maintain their current dose regimen.
Continued treatment After a 30-day washoutNon-stimulant medications 
used to treat ADHD
Therapies for cognitive 
dysfunction used for symptomatic treatment of PASC or premorbid cognitive symptoms
Narcotics
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
16  
6.4.2  ALTERNATIVE THERAPY  
Transcranial magnetic stimulation and electroconvulsive therapy are NOT permitted during the study 
period . Any lifetime use of electr oconvulsive therapy is exclusionary, but previous use of trans cranial 
magnetic stimulation is permitted  as long as it has not been performed within 30 days of study 
initiation.   
6.4.3  RESCUE MEDICINE  
Participants who require a rescue medication to treat a  non- study- related  acute condition during the 
study period should proceed with treatment for the acute condition , as prescribed by  their treating 
clinician. They may continue  receiving  the intervention regardless of the medication.  
 
7 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  
 
7.1 PARTICIPANT DISCONTINUATION  FROM I NTERVENTION  
Discontinuation from an intervention  does not mean discontinuation from the study, and remaining 
study procedures should be completed as indicated by the study protocol. If a clinically sig nificant 
finding is identified (such as  changes from baseline) after enrollment, the investigator or quali fied 
designee will determine if any change in participant management is needed.  
An investigator may use his/her discretion to discontinue a participant from the intervention  for any 
reason , including, but not limited to, one of the following: Drug class/Therapy Generic name
(examples)Brand name
(examples)Allowed Prohibited N otes
diazepam Valium
alprazolam Niravam, Xanax
triazolam Halcion
lorazepam Ativan, Loreev
clonazepam KlonoPIN
atropine Atropen
scopolamineMaldemar, Scopace, Transderm 
Scop
trihexyphenidyl Artane, Trihexane, Tritane
benztropine Cogentin
fluoxetine PROzac, Rapiflux, Sarafem
duloxetine Cymbalta
citalopram Celexa
sertraline Zoloft
paroxetine Paxil, Pexeva
escitalopram Lexapro
mirtazapine Remeron
bupropion Wellbutrin
Electroconvulsive therapy None Any history of use
Transcranial magnetic 
stimulation therapyAfter a 30-day washout Continued treatmentSystematically 
administered (eg, oral, 
IV, IM, etc.) 
anticholinergics are 
e
xclusionary, unless it 
is washed out for 30 
days prior to randomization.Non-systemically 
administered (eg, inhaled, 
topical) anticholinergics, 
like the inhaled agents for 
br
onchospasm, regardless 
of frequency and dose
Dose should be stable ≥ 90 
days before randomization and 
maintained for study duration. A 
necessary change in dose does 
no
t cause discontinuation, but 
the dose change must be documented in the EDC.All other instances of 
antidepressant use 
after  PASC diagnosis 
ar
e exclusionary, 
unless it is washed out 
for 30 days prior to 
randomization.Participants who were on 
stable doses of 
antidepressants before 
t
heir PASC symptoms will 
not need to washout, can 
maintain their current dose regimen.Use must be refrained within 48 
hours prior to assessments; 
failure to refrain will require rescheduling of the 
a
ssessments. All other instances of 
benzodiazepine use are 
exclusionary, such as 
higher frequency and 
d
oseOccasional use (1-2 
times/week) of low-dose benzodiazepines according to local standards.
A
ll other instances of 
benzodiazepine use after a 
30-day washout before 
randomizationBenzodiazepines
Anticholinergics
Antidepressants
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
17 • Significant study intervention non- compliance  
• If any clinical AE, laboratory abnormality, or other medical condition or situation occurs such 
that continued participation in the study would not be in the best interest of the participant  
• Confirmed new case of acute SARS-CoV-2 
The reason for participant discontinuation from an intervention will be recorded on the CRF. Participants 
who are discontinued from the intervention , but who are not withdrawn from the study , will continue to 
be followed for all study procedures. If participants discontinue an intervention, but do  not withdraw 
consent, they will be followed for safety for at least 28 days.   
7.2 PARTICIPANT  WITHDRAWAL  FROM THE STUDY  
Participants are free to withdraw from participation in the study at any time upon request.  The study 
team will attempt to determine a reason for withdrawal ; however, participants are not obligated to 
provide a reason for withdrawal. If obtained, the reason for withdrawal will be recorded on the CRF. No 
further study procedures will be performed and no further data will be collected from the participant 
following study withdrawal. All of the data collected up until the time of withdrawal will be maintained in the study database  and will be used as the participant’s data are evaluable for analysis .    
7.3 LOST TO FOLLOW -UP 
 
Participants will be considered lost to follow -up if they fail  to return for any scheduled visit and  if they 
are unable to be contacted after multiple attempts and methods by the study site  staff .  
 The following actions must be taken if a participant fails to return for a required study visit:  
• The site will attempt to contact the participant , reschedule the missed visit, counsel the 
participant on the importance of maintaining the assigned visit sche dule , and ascertain if the 
participant wishes to and/or should continue in the study . 
• Before a participant is deemed lost to follow -up, the investigator or designee will make every 
effort to regain contact with th e participant or next of kin (where possible, telephone calls and, 
if necessary, a certified letter to the participant’s last known mailing address or local equivalent 
methods). These contact attempts should be documented in the participant’s medical record or 
study file.  
• Should the participant  continue to be unreachable,  after exhausting all methods,  he or she will 
be considered to have withdrawn from the study with a primary reason o f lost to follow -up. 
 
7.4 STUDY HALTING RULES  
The Data and Safety Monitoring Board (DSMB) will review study data at a regular frequency. During 
DSMB review, study enrollment and intervention- specific activities will continue. However, if the DSMB 
recommends to discontinue study activities, study enrollment and intervention- specific activities will be 
temporarily suspended while the NIH and the study Co -Principal Investigators consider the DSMB 
recommendations prior to making decisions on study continuation or discontinuation.  
 
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
18 8 STUDY ASSESSMENTS AN D PR OCEDURES  
 
8.1 SCHEDULE OF P ROCEDURES  
This table displays the general activities schedule for all interventions; however, intervention- specific 
activities that differ will be listed in the intervention appendix. 
Table 3. Schedule of study p rocedures  
 Screening  Baseline1 Start of 
Intervention  Middle of 
Intervention  End of 
Intervention  End of 
Study  
PROCE DURE Day 
-14 to 0  Day 
-4 to 0  Day 0  
+ 21 days  MOI  
± 3 days EOI 
± 3 days EOI 
+ 90 d ays 
(±3 days)  
Informed consent  X      
Demographics  X      
Medical history  X      
COVID treatment   X     
Blood pressure , heart rate,  
weight   X   X X 
Height  X      
Concomitant medication /therapy  X X  X X X 
Appendix -level eligibility criteria  X      
PROMIS -Cog X    X X X 
ECog2   X  X X X 
Neurocognitive battery   X   X X 
Exploratory PROs    X2   X2  X2 X2 
Randomization   X     
Safety assessment   X X X X  X3 
DSQ -PEM , twice weekly    X X X  
Nasal swab   X     
Pregnancy test   X     
Biorepository collection   X4   X4 X5 
                                                             
1 Baseline assessments may occur on the same day as Scree ning  
2 The DSQ -PEM will be performed the immediate next day after completing the neurocognitive battery  (Baseline, EOI, EOS) or 
study visit (MOI) . 
3 As needed per intervention  
4 Blood and stool collection  
5 Blood collection only, no stool  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
19  
8.2 SCREENING  (DAY -14 TO 0)  
The trial’s  activities, benefits and risks, and other treatment options will be thoroughly explained to 
potential participants. After obtaining informed consent, the following assessments will be  performed at 
screening to determine eligibility : 
• Demographics  
• Medical h istory  
• Height  
• Collection of concomitant m edication s/therapies  taken /received  within 14 days of informed 
consent  
• PROMIS -Cog* 
• Review appendix -level eligibility criteria, refer to appendices  
*If Baseline activities do not begin within 7 days of the participant completing the PROMIS -Cog, the 
PROMIS -Cog must be re -completed, with an inclusive score, before Baseline activities begin.  
Participants who fail screening may be re -screened one time. Re- screening more than once is at the site 
investigator’s discretion.  
8.3 BASELINE  (DAY -4 TO 0)  
Baseline assessments may occur on the same day as Screening. The following will occur at the Baseline 
visit:  
• Blood pressure, heart rate, and weight  
o Blood pressure and heart rate measurements should be obtained in the supine and 
standing positions: Supine measurements will be taken after the participant lies supine 
for 5 minutes, and then standing measurements after the participant stands for 1 minute.  
• COVID treatment, including infection dates, treatment histor y, and vaccine use  
• Concomitant medication /therapy  review  
• ECog2  
• Neurocognitive battery, including the World Health Organization- University of California Los 
Angeles  Auditory Verbal Learning Test  (WHO -UCLA AVLT) , Symbol Digit Modalities Test, Verbal 
Fluency (lexical + semantic), Digit Vigilance Test, Cogstate tests  (Detection, Identification, One 
Back ), and NIH Toolbox Flanker Inhibitory Control and Attention Test  
• Exploratory PROs, including PROMIS -29+2 , PROMIS -Fatigue , PROMIS -8a SRI and 8b SD , PASC 
Symptom Questionnaire , and DSQ -PEM  
o The DSQ -PEM will be performed the immediate next day after completing the 
neurocognitive battery.  
• Biorepository, b lood and stool c ollection  (frozen for retrospective analysis)  
• Urine or blood pregnancy test  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
20 • Nasal Swab , for SARS-CoV-2 rapid antigen test  
• Safety assessment , including S erious Adverse Events (S AEs), Suspected Unexpected Serious 
Adverse Reaction ( SUSARs ), and Events of Special Interest ( ESIs) 
• Randomization  
Participants should take their medication  relative to assessments  at consistent  intervals  across all 
timepoints . Similarly, the time of day assessments are scheduled should be as consistent as possible 
across all time points for each participant.  
8.4 START OF INTERVENTION (DA Y 0 + 21 DAYS ) 
See appendices  for details . Safety assessments, including SAEs, Unanticipated Adverse Device Effects 
(UADEs), SUSARs, and ESIs, will occur at the start of intervention and continue until EOI.  
The DSQ -PEM will be given twice weekly during the intervention, from the Start of Intervention to EOI. 
The 2 weekly surveys must be separated by at least 48 hours. A DSQ -PEM administered 24 hours after 
the Baseline , MOI , and EOI  visits will not count as one of the two weekly surveys , ie, 3 surveys will be 
administered in those weeks .  
8.5 MIDDLE OF INTERVENTI ON (MOI ± 3  DAYS)  
The Middle of Intervention visit is designed to be fully remote for all interventions. The following will 
occur:  
• Concomitant medication/therapy review  
• PROMIS -Cog 
• ECog2  
• Exploratory PROs, including PROMIS -29+2, PROMIS -Fatigue , PROMIS -8a SRI and 8b SD , PASC 
Symptom Questionnaire , and  DSQ -PEM  
o The DSQ -PEM will be performed the immediate next day after completing the study 
visit.  This does not  count as one of the two weekly administrations.  
• Safety assessment , including SAEs, UADEs, SUSARs, and ESIs  
• DSQ -PEM, twice weekly , separated by at least 48 hours  
8.6 END OF INTERVENTION (EOI ± 3 DAYS)  
The End of Intervention visit will occur ± 3 days after completing the intervention requirements and 
duration (see Appendices). The following will occur at the End of Intervention visit:  
• Blood pressure , heart rate,  and weight  
o Perform blood pressure and heart rate per the procedure explained in the Baseline visit.  
• Concomitant medication /therapy  review  
• PROMIS -Cog 
• ECog2  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
21 • Neurocognitive battery, including the modified -Rey Auditory Verbal Learning Test  (RAVLT) , 
Symbol Digit Modalities Test, Verbal Fluency (lexical + semantic), Digit Vigilance Test, Cogstate 
tests  (Detection, Identification, One Back ), and NIH Toolbox Flanker Inhibitory Control and 
Attention Test  
• Exploratory PROs, including PROMIS -29+2 , PROMIS -Fatigue, PROMIS -8a SRI and 8b SD , PASC 
Symptom Questionnaire , and DSQ -PEM  
o The DSQ -PEM will be performed the immediate next day after  completing the 
neurocognitive battery.  
• Biorepository, b lood and stool c ollection  (frozen for retrospective analysis)  
• Subjective Global Assessment Questionnaire  
• Safety assessment , including SAEs, UADEs, SUSARs, and ESIs  
• DSQ -PEM, twice weekly , separated by at least 48 hours  
8.7 END OF STUDY (EOI + 90 DAYS  (±3 DAYS) ) 
The following will occur at the End of Study visit:  
• Blood pressure , heart rate,  and weight  
o Perform blood pressure  and heart rate  per the procedure explained in the Baseline visit.  
• Concomitant medication /therapy  review  
• PROMIS -Cog 
• ECog2  
• Neurocognitive battery, including the WHO -UCLA  AVLT , Symbol Digit Modalities Test, Verbal 
Fluency (lexical + semantic), Digit Vigilan ce Test, Cogstate tests  (Detection, Identification, One 
Back ), and NIH Toolbox Flanker Inhibitory Control and Attention Test  
• Exploratory PROs, including PROMIS -29+2 , PROMIS -Fatigue, PROMIS -8a SRI and 8b SD , PASC 
Symptom Questionnaire , and DSQ -PEM  
o The DSQ -PEM will be performed the immediate next day after completing the 
neurocognitive battery.  
• Biorepository, b lood c ollection  (frozen for retrospective analysis)  
• Subjective Global Assessment Questionnaire  
• Safety assessment , including SAEs, SUSARs, and ESIs, as needed per appendix  
8.8 CLINICAL LABORATORY ASSESSMENTS  
Clinical laboratory assessments, such as Complete Blood Count  and Comprehensive Metabolic  Panel , 
may be required as part of Baseline  assessments. If a participant has  these laborator y assessments 
available within 3  months of study enrollment, they do not need to be repeat ed as part of the study . See 
the relevant appendix for requirements.  
8.9 STUDY  ASSESSMENTS  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
22 The following assessments  will occur according to the Schedule of Procedures ( Table 2). The objective 
assessments in the secondary outcome will be administered at each study site by at least one person, 
who will be required to receive training in measurement tool administration (see MOP for details).  
8.9.1  EVERYDAY COGNITION 2  (ECOG 2) 
The ECog2 is a self -report, 41 -item questionnaire used to measure the participant’s perceived capac ity 
to perform activities related to cognitive function, which could impact major activities of daily living and independence.
36 It has been used for patients with mild cognitive impairment,37 Alzheimer’s Disease,38 
and dementia.39 It takes 5 minutes to complete.  
8.9.2  PROMIS -COG  
The PROMIS -Cog is the PROMIS short form for the cognitive function domain and is a self -report, 8 -item 
questionnaire targeting cognitive function in the past seven days.40 It is a r eliable measure with 
normative data,41 and takes 2 minutes to complete .  
8.9.3  EXPLORATORY PROS  
 
8.9.3.1  PROMIS -29+2 
Patient -Reported Outcomes Measurement Information System ( PROMIS -29) global health scale: The 
PROMIS was developed out of the “Roadmap for Medical Research” created by the NIH in 2002 as valid, generalizable items to standardize clinical research across NIH -funded research dealing with PROs. 
Multiple PROMIS scales have been validated across many clinical populations.
42 The PROMIS -29 consists 
of 29 items that assess general domains of health and functioning, including overall physical health, 
mental health, social health, pain, fatigue, and overall perceived quality of life. The PROMIS  global 
health scales  has been correlated  against the EuroQol EQ -5D.43 Additionally, PROMIS  scales  have been 
used with PASC patients.44  
The PROMIS -29+2 is used to calculate a preference score (PROPr ) by the addition of two Cognitive 
Function Ability items. Preference -based scores provide an overall summary of HRQOL on a common 
metric. Preference- based scores summarize multiple domains on a metric ranging from 0 (as bad as 
dead) to 1 (perfect or ideal  health). Scores can be used in comparisons across groups and for cost -utility 
analyses. It takes 8 minutes to complete.  
8.9.3.2  PROMIS -FATIGUE  
The PROMIS -Fatigue is the PROMIS short form for the fatigue domain and is a self -report, 10 -item 
questionnaire that assesses a participant’s fatigue on a scale of 1 (not at all fatigued) to 5 (very much). It 
targets  fatigue and its impacts on daily living in the past seven days.40 It is a reliable and valid measure of 
fatigue across diverse clinical populations.45 It takes 2 minutes to complete.  
8.9.3.3  PROMIS -8A SRI AND 8B SD 
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
23 The PROMIS 8a SRI and 8b SD were developed as short forms from the PROMIS SD and SRI. The 8 -item 
short forms are strongly correlated with the long forms and have greater precision than other commonly 
used sleep assessments such as the Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale. The PROMIS 8 b SD form includes a total of 8- items that ask participants to reflect on their sleep over the 
past 7 days with one question rated very poor to very good and the remaining questions rated not at all to very much. The PROMIS 8a SRI form includes a total of 8- items that ask participants to reflect on their 
sleep over the past 7 days with questions rated not at all to very much.  They take 5 minutes to 
complete.  
8.9.3.4  PASC SYMPTOM QUESTIO NNAIRE 
The PASC Symptom Questionnaire is a self -report measure for reporting multiple PASC -related 
symptoms ac ross multiple systems. For this platform protocol, two additional sleep- focused questions 
will be included. It takes 3 minutes to complete.  
8.9.3.5  MODIFIED DEPAUL SYMP TOM QUESTIONNAIRE PO ST EXERTIONAL MALAIS E 
The DSQ PEM is a subset  of the DSQ that assesses PEM.46 This scale assesses symptom frequency a nd 
severity over the previous  6-month period; however, for the purposes of this trial , the look -back period  
will be modified to “since the previous visit” when administered at Baseline, MOI, EOI, and EOS. When 
administered twice weekly, the look -back period will be “the past 7 days .” This form  was previously 
validated in patients with myalgic encephalomyelitis/chronic fatigue syndrome. It takes less than 5 
minutes to complete.  
8.9.3.6  SUBJECTIVE GLOBAL AS SESSMENT QUESTIONNAIRE  
The Subjective Global Assessment Questionnaire  asks participants to self -report whether the 
intervention helped their symptoms and whether they think they received an active intervention or active comparator. It takes 2 minutes to complete.  
8.9.4  NEUROCOGNITIVE BATTE RY 
The neurocognitive battery includes measures of objective cognitive function utilizing well -validated, 
psychometrically robust tests of attentional capacity, executive skill, and memory function.  These 
measures objectively characterize the following:  
Learning and Memory:  
• Verbal list learning over repeated trials, free recall, and recognition memory  
Executive Attentional and Processing Speed Skills:  
• Timed sequencing of two sets of stimuli according to a key  
• Vigilance tasks: Stimuli identification among simple and complex distractors  
• Verbal fluency  
• Measures of attention:  
o Simple reaction time; respond when X happens  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
24 o Choice reaction time; respond only if X happens  
Concentration/working memory; yes/no does new stimuli match previous stimuli  
The neurocognitive battery includes the objective measures in the following subsections.  
8.9.4.1  AUDITORY VERBAL LEAR NING TEST S 
The WHO- UCLA AVLT  will be used at Baseline and EOS, while a modified- RAVLT will be used at EOI.  
The RAVLT is a robust test for clinical assessment of learning and memory and has been validated in 
English and Spanish.47,48 The recognition list will be modified  to match the number of words in the WHO -
UCLA AVLT word list.  
Both the  RAVLT and WHO -UCLA AVLTare  auditory list -learning tests that assess learning and memory 
and is sensitive to cognitive dysfunction. The test s involve five free recall trials of 15 words, a short 
delayed recall, a long delayed recall, and a recognition tria l.49 The WHO- AVLT has also been validated i n 
Spanish- speaking populations .50  
For both AVLTs, t he learning trials take 8 minutes to complete, and recall and recognition trials take 5 
minutes. Other nonverbal tasks or subjective scales can be administered during the delay period.  
8.9.4.2  SYMBOL DIGIT MODALITIES TEST  
The Symbol Digit Modalities Test is a neuropsychological executive task measuring sequencing/coding 
and processing speed.51 It takes 5  minutes to complete.  
8.9.4.3  VERBAL FLUENCY  
Verbal Fluency includes neuropsychological measure s of lexical and semantic fluency.52 Each  take 3 
minutes to complete.  
8.9.4.4  DIGIT VIGILANCE 
Digit Vigilance is a neuropsychological executive task measuring sustained attention, vigilance, and processing speed.
53 It takes 10 minutes to complete.  
8.9.4.5  COGSTATE 
Cogstate is a commercially available platform of objective neuropsychological tests for measuring 
distinct cognitive functions: the Detection Test targeting psychomotor function, the Identification Test targeting attention, and the One Back Test targeting working memory.
54 The Cogstate is validated for 
telehealth assessment55 and cognitive impairment.56 It takes 3 -4 minutes to complete each test, about 
12 minutes total.  
8.9.4.6  NIH TOOLBOX FLANKER INHIBITORY CONTROL A ND ATTENTION TEST 
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
25 The Flanker Test measures both a participant’s attention and inhibitory control.57 The test requires the 
participant to focus on a stimulus while inhibiting attention to stimuli flanking the stimulus. Scoring is 
based on a combination of accuracy and reaction time. It takes 3 minutes to complete.  
8.10  BIOREPOSITORY FOR F UTUR E RESEARCH  
The RECOVER Biorepository is designed to collect and store biospecimens, such as blood plasma and serum samples , for future research related to the various studies of the RECOVER Program. Such 
research might include developing diagnostic and/or prognostic tests, improving our understanding of the underlying pathophysiology of PASC , and developing new therapeutic targets. Samples from 
biorepositories have proven to be enormously important in the last 20 years, as information on the components of b lood has expanded rapidly. Important insights have been gained from biorepository 
samples from clinical trials and the stored samples from the RECOVER Program will prove equally 
productive and important. This B iorepository will be conducted under the coordination of the Duke 
Clinical Research Institute (DCRI) which serves as the CT -DCC for all RECOVER clinical trials.  
The existence of the RECOVER B iorepository will provide the opportunity to devise new hypotheses, 
since blood collection techniques are standardized across all approved protocols , thereby allowing 
cross -protocol sample comparisons if scientifically justified.  
Within thi s framework, the design of the B iorepository is to collect  stool, plasma, and serum  for storage 
in the Biorepository for future, as yet unspecified, analyses , and studies. At each time point including 
blood collection, e ighty (80) mL of blood will be collected to prepare the aliquots for storage at - 80 °C. 
For this protocol, blood will be collected at Baseline, EOI, and EOS. These samples will be stored at the 
Biorepository in a lab for up to 7 years. See the MOP for details  of blood and stool collection .  
 
9 SAFETY  ASSESSMENTS AND REPORTING 
 
9.1 SAFETY EVENTS  
 
9.1.1  DEFINITION OF SAFETY EVENTS  
An Adverse Event ( AE) is any untoward medical occurrence in humans, whether or not considered drug- 
or intervention -related, which occurs during the conduct of a clinical trial. An AE can therefore be any 
change in clinical status, routine labs, x -rays, physical examinations, etc., that is considered clinically 
significant by the study investigator.  
A Serious Adverse Event ( SAE) or serious suspected adverse reaction  (SAR)  or serious adverse reaction , 
as determined by the investigator or the sponsor , is an AE that results in any of the following serious 
outcomes:  
• Death  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
26 • Life-threatening AE (“ Life-threatening” means that the study participant was, in the opinion of 
the investigator or sponsor, at immediate risk of death from the reaction as it occurred and 
required immediate intervention .)  
• Persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions  
• Inpatient hospitalization or prolongation of existing hospitalization  
• Congenital abnormality or birth defect  
• Important medical  event that may not result in one of the above outcomes, but may jeopardize 
the health of the study participant or require medical or surgical intervention to prevent one of 
the above outcomes  from occurring   
 
An Adverse Device Effect (ADE) is an event rel ated to the use of an investigational medical device. This 
includes any AE resulting from insufficiencies or inadequacies in the I nstructions for U se, deployment, 
implantation, installation, or  operation, or any malfunction of the investigational medical device. An ADE 
also includes any event resulting from  a use error or intentional misuse. 
• Device malfunction –  the failure of a device to perform in accordance with the I nstructions for 
Use or cli nical investigative plan.  
• User error or intentional misuse –  a device is used in a manner that is an act or omission of an 
act that results in a different medical device response than intended by the manufacturer or 
expected by the user.  
An Unanticipated A dverse Device Effect (UADE) is any serious adverse effect, problem, or death caused 
by or associated with a device if that effect was not previously identified in nature, severity, or degree of 
incidence in the investigational plan or application (including a supplementary plan or application), or 
any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.  Unanticipated Adverse Device Effects  will include events meeting either A or B as 
stated  below:  
A. Events meeting ALL of the following criteria:  
• Not included in the relevant appendices, product label , or Instruction for U se 
• Related to the investigational device per the site principal investigator and/or IND sponsor  
• Serious (meets any of the foll owing criteria):  
o Is life -threatening illness or injury 
o Results in permanent * impairment of a body function or a body structure  
o Necessitates medical or surgical intervention to prevent permanent * 
impairment of a body function or a body structure  
o Results in hospitalization  
o Led to fetal distress, fetal death or a congenital abnormality or birth defect  
o Led to death  
*Permanent  means irreversible impairment or damage to a body structure or 
function, excluding trivial impairment or damage.  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
27 B. Any other unanticipated serious problem associated with the investigational device that relates 
to the rights, safety, or welfare of subjects.  
Hospitalization for elective treatment of a preexisting condition that did not worsen from baseline does 
not meet the definition of an SAE. Hospitalization is defined as a stay in the hospital exceeding 24 hours.  
An unexpected AE  is defined as any AE  or ADE, the specificity or severity of which is not consistent with 
the study drugs’  package insert  or devices’ Instruction for Use . 
An unanticipated problem involving risk to human subjects or others, including an environmental 
exposure and exposure to a breastfeeding infant, will be reported to the sponsor and the site IRB and central IRB, as appropriate. The event will not be entered into the electronic data capture ( EDC) system . 
Refer to the MOP and/or Safety Management Plan (SMP) for details.   
If an intervention includes study drug(s) and m edication errors result  in an SAE , the errors  are 
reportable. The medication error will be captured as a protocol deviation and the SAE captured on the SAE electronic Case Report Form ( eCRF ).  
9.1.2  COLLECTION PERIOD OF  AE AND SAE INFORMAT ION  
Safety event  collection will occur at the pre -specified study visits , but a ll participants will be instructed 
to self -report concerns by calling the site.  
Serious adverse events (SAEs) , UADEs, or ESIs will be extracted by site pers onnel from the participant’s 
medical record if the participant seeks medical care or if hospitalization occurs, each of which notifies the site to conduct follow -up.  
Medical occurrences that begin before intervention procedures, but after obtaining informed consent, will not be considered an AE.  The medical occurrence or condition will be captured on the Medical 
History eCRF.  
Non- serious AEs may be reported by the participant, but will not be  collected to the study database or  
further assessed by the site or study personnel. However, a ny non- serious AEs or ADEs that result in 
intervention discontinuation will be reported as an AE or ADE in the study database and identified as the reason for discontinuation in the study database, and these non- serious AEs an d ADEs  will be collected 
from the start of intervention  administration through the end of intervention procedures . 
Any AEs that are also classified as symptoms associated with PASC and collected during the study will 
not be collected  as a safety event to the study database or further assessed by the site or study 
personnel  because they will be collected as part of the PASC symptom dataset .  
Serious adverse events  (SAEs ) will be collected from  the first study procedure  through the End of Study 
visit [(EOI + 90 days)  ± 7 days ].  
Adverse events (AEs) that qualify as an ESI , even if a non -serious AE,  will be collected from the start 
intervention procedures  through the End of Study visit  [(EOI + 90 days)  ± 7 days ]. A UADE observed  from 
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
28 the time of start of intervention through the end of the intervention will be collected in the clinical 
database.  
9.1.2.1  SEVERITY OF EVENT  
For reportable events , the following guidelines will be used to describe severity.  
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities . 
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause som e interference with functioning. 
• Severe – Events interru pt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life -threatening or 
incapacitating . Of note, the term  “severe” does not  necessarily equate to “serious ” for 
regulatory reporting. 
 
 
9.1.2.2  RELATIONSHIP TO STUD Y INTERVENTION  
All reportable events  must have their relationship to the study intervention assessed by the clinician, 
who examines and evaluates the participant based on temporal relationship and his or her clinical 
judgme nt. The degree of certainty about causality will be graded using the categories below. In a clinical 
trial, the study product must always be suspect.  
• Related  – The AE or ADE is known to occur with the study intervention , a reasonable possibility  
exists  that the study intervention caused the AE  or ADE, or a temporal relationship subsists 
between the study intervention and event. Reasonable possibility means that evidence suggest s 
a causal relationship between the study intervention and the AE  or ADE. 
• Not Related  – No reasonable possibility exists that the administration of the study intervention 
caused the event, no temporal relationship subsists between the study intervention and event 
onset, or an alternat e etiology has been established. 
9.1.3  TIME PERIOD AND  FREQUENCY FOR EVENT  ASSESSMENT AND FOLL OW-UP 
The occurrence of an AE, ADE, ESI, or SAE may come to the attention of study personnel during study 
visits and interviews of a study participant presenting for medical care, or upon review by a study monitor. 
All reportable events will be captured on the appropriate  CRF. Information to be collected includes 
event description, date/ time of onset, clinician’s assessment of severity, relationship to intervention  
product (assessed only by those with the training and authority to make a diagnosis), action taken with 
intervention product (e.g. discontinuation), and date/ time of resolution/stabilization of the event. All 
events occurring within the pre -specified reportable time windows must be documented appropriately 
regardless of relationship.  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
29 Any medical condition that is present at the time the participant is screened will be considered as 
baseline and not reported as a  safety event . However, if the study participant’s condition deteriorates at 
any time during the study, it will be recorded as a  safety event .  
Changes in the severity of a  safety event  will be documented to allow an assessment of the duration of 
the event at each level of severity to be performed. Safety events  characterized as intermittent require 
documentation of onset and duration of each episode.  
The investigator will follow all SAEs  or UADEs until resolution, stabilization , or the event is otherwise 
explained. The  DCRI  Safety Surveillance Team will follow all SAEs or UADEs until resolution, stabilization,  
or until otherwise explained.  
9.1.4  REPORTING AND M ONITORING OF SAES  AND UADES  
When an intervention appendix comprises a study drug(s), the study drug(s) may be under an IND and 
subject to IND regulations in 21 CFR 312, especially if their investi gational use for treatment of PASC is 
not an approved indication. In such a case, the IND sponsor, DSMB, or Study Medical Monitor will review 
aggregate safety data. The IND sponsor or designee will be responsible for determining if the safety reporting cri teria are met per 21 CFR 312.32(c)(1)(i)(C) and 21 CFR 312.32(c)(1)(iv) and will notify the CT -
DCC to prepare an aggregate report for submission to the US Food and Drug Administration ( FDA). An 
aggregate safety report will be submitted to FDA as soon as possible, but in no case later than 15 calendar days after the IND sponsor determination. If the IND sponsor determines that an unexpected 
fatal or life -threatening SAR occurs markedly more frequently in a study drug arm than in the 
comparator  arm, an aggregate safety report will be submitted to the FDA as soon as possible, but in no 
case later than 7 calendar days after the IND sponsor determination. Information on individual SAEs will 
be available upon request from the FDA  following the submission of any aggregate reports.  
Any UADE that the I DE sponsor determines is/are reportable will be submitted to the FDA, 
manufacturer, all reviewing IRBs, and all participating investigators within 10 working days of when the 
sponsor makes that determination. Any fatal o r life -threatening UADE the IDE sponsor determines is 
reportable will be submitted to the FDA, manufacturer, all reviewing IRBs and all participating 
investigators within 5 working days of notice of the effect.  
If the I DE sponsor determines the UADE presents an unreasonable risk to participants, all investigations 
or parts of investigations presenting that risk shall be terminated as soon as possible. Termination shall occur not later than 5 working days after the I DE spon sor makes this determination and no later than 15 
working days after the sponsor first received notice of the effect.  
Individual SAEs or UADEs must be entered into the data system within 24 hours of site awareness. The DCRI Safety Surveillance team will n otify pharmaceutical partners of SAEs and device manufacturer of 
UADEs within 1 to 2 business day s of their receipt that occur involving the specific appendix of the 
supplied study intervention /comparator , as required. Serious Adverse Events that are relat ed and 
confirmed unlisted by the DCRI Safety Medical Monitor and IND sponsor will be reported to the FDA as SUSARs; as 7 -day reports for unexpected fatal or life -threatening adverse reactions and 15- day reports 
for serious and unexpected adverse reactions.  The SUSAR s will be shared with the pharmaceutical 
partner of the supplied study drug according to the same timelines . If the IND sponsor, DSMB , or FDA 
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
30 note a clinically important increase in the rate of a SUSAR, the IND sponsor or designee will notify 
investigators no later than 15 calendar days after determining that the information qualifies for reporting. The investigator s will notify their local IRB according to local guidelines if applicable. The CT-
DCC will notify the central IRB.  Refer to the SMP for details regarding specific reporting timelines.  
Investigators are not obligated to actively seek information on AEs or SAEs after the participant has  
concluded study participation. However, if the investigator learns of any SAE, including a death, at any time after a participant has completed the study (but before the study itself has ended), and they consider the event to be reasonably related to the study intervention, the investigator must promptly report the SAE to the sponsor via EDC entry.  
9.1.5  EVENTS OF SPECIAL IN TEREST  
Each intervention  may have a unique list of ESIs. Refer to the relevant appendix . 
9.1.6  REPORTING OF PREGNAN CY 
Pregnancies occurring after  starting intervention activities  and while on -study will be documented in the 
database . Pregnant  participants  will be advised  to discontinue the intervention . Upon discovery of a 
pregnancy, the study team will ask pregnant participants to complete a pregnancy- specific consent form  
in order to  follow the pregnancy to its outcome in the case the outcome is not reached while the 
participant is on- study (i.e., occurs after EOS) . Male participants on- study who conceive a child should 
notify the study team,  which will request consent of the mother to follow the pregnancy to its end 
result. Within 1 to 2 business days after learning of the pregnancy, the DCRI Safety Surveillance team 
will notify study -drug or device supplying partners of the  pregnancy, as required. Lastly, a ny pregnancy-
associated ESI or SAE should be reported if information can be collected and entered into the CRF . Any 
appendix -specific changes to these reporting requirements are expressly stated in the specific appendix.  
 
10 STATISTICAL CONSI DERATIONS  
 
10.1 GENERAL CONSIDERATIO NS 
All statistical analyses will be performed using SAS (SAS Institute, Inc. Cary, NC, USA) version 9.4 or higher. Baseline demographic and clinical data will be summarized by intervention arm. Descriptive statistics will inc lude mean, standard deviation, median, 25
th and 75th percentiles for continuous 
variables and frequency and percentage for categorical variables. Statistical comparisons will be performed using two -sided tests at 0.05 significance level. The primary analys es will not be adjusted for 
multiplicity of comparisons since each intervention appendix can be justified as a separate experiment, as opposed to a part of a family of related experiments (see Proschan and Waclawiw, 2000).
58 Analyses 
of the secondary endpoints will not be adjusted for multiplicity of comparisons and the results of these analyses will be considered exploratory. 
 Additional details regarding statistical analyses will be provided 
in the SAP which will be finalized  prior to the database lock.  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
31 10.2 STATISTICAL HYPOTHES ES 
 
Primary Endpoint:  
1. Less dysfunction on ECog2 at the EOI compared to baseline in intervention in compari son to 
comparator  condition 
Secondary  Endpoints : 
1. Less dysfunction on the PROMIS -Cog at EOI and at EOS compared to baseline in intervention in 
comparison to comparator  condition 
2. Less dysfunction on neurocognitive  battery  assessments ( AVLT , Symbol Digit, Verbal Fluency, 
Digit Vigilance, Cogstate , Flanker ) at EOI  and at EOS  compared to baseline in intervention in 
comparison to comparator  condition 
3. Less dysfunction on ECog2 at EOS compared to baseline in intervention in comparison to 
comparat or condition 
4. Study interventions are safe in the PASC population  
10.3 SAMPLE SIZE  DETERMINATION  
This study uses an adaptive platform trial design that will allow interventions  to be added or dropped 
from consideration based on accruing evidence of futility or efficacy , whichever is appropriate to the 
intervention . In such a design, the required sample size depends on both the number of interventions  
tested and the ability to pool their comparator  arms for analysis. Initial sample size estimates are based 
on a s tudy with a single intervention  and 1:1 allocation to active intervention  or comparator . If 
additional interventions  are added later  that can contribute to pooled comparator , the sample size will 
be adjusted accordingly.  
See the appendices for intervention -specific  details of  sample size determination.  
10.4 POPULATIONS FOR ANALYSES  
Population for effectiveness analyses:  ITT. The primary  efficacy analysis will be based  on a n intention -
to-treat (ITT)  population. All  randomized participants  will be included and  will be  analyzed  according to  
their assigned intervention  group.   
Safety population.  Safety  analyses will  be perfo rmed among participants in the ITT  population who 
report completing at least one intervention activity, which is aimed at addressing a study outcome, in 
the intervention or comparator . Participants  will be analyzed according to  their  assigned intervention  
groups.  
10.5 STATISTICAL ANALYSES  
This section describes analysis methods for the primary, secondary, and safety outcomes. Full deta ils will 
be provided in the SAP . 
10.5.1  ANALYSIS OF THE PRIM ARY ENDPOINT  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
32 The primary endpoint analys is will be performed using a linear regression model with change of ECog2 
from baseline to  EOI as an outcome. The analysis model will include intervention  arm indi cator variables 
and will be adjusted for baseline ECog2, age, sex , education level , and primary language (English vs. 
Spanish) . The normality assumption for the outcome distribution will be evaluated. If this assumption is 
not met, outcome transformations or regression models with different distributional assumptions may 
be utilized. 
10.5.2  ANALYS ES OF THE SECONDARY E NDPOINT(S)  
PROMIS -Cog.  The PROMIS -Cog is a continuous measure. Changes in total score from baseline to EOI and 
to EOS will be analyzed using similar methods as those outlined for the primary endpoint.  
Neurocognitive dysfunction: Neurocognitive battery ( AVLT , Symbol Digit, Verbal Fluency, Digit 
Vigilance, Cogstate , Flanker ). Each of the neurocognitive assessments results in a continuous score. 
Changes from baseline to EOI and to EOS for each neurocognitive outcome will be analyzed using similar methods as those outlined for the primary endpoint. 
ECog2 at EOS. Change in ECog2 from baseline to EOS will be analyzed using similar methods as those 
outlined for the primary endpoint.  
Safety endpoint s. Safety endpoints include the proportion of participants who experience individual 
SAEs/UADEs  and the proportion who experience any one or more SAEs /UADEs . These will be analyzed in 
the safety popul ation . Events of Special Interest (ESIs)  will be summarized  by intervention appendix . 
Incidence of AEs/SAEs/UADEs  leading to discontinuation will also be summarized.  
10.5.3  ANALYSIS OF THE EXPL ORATORY ENDPOINT(S)  
PROMIS -29+2, PROMIS -Fatigue , PROMIS -SRI, PROMIS -SD, DSQ- PEM, and PASC Symptom 
Questionnaire . These PROs are continuous measures. Changes from baseline to EOI and to EOS will be 
analyzed using similar methods as those outlined for the primary endpoint.  
10.5.4  MISSING DATA 
The primary and secondary analyses will be performed without missing data imputation. Additional sensitivity and supplementary analyses with adjustments for missing data will be described in the SAP. 
10.5.5  PLANNED INTERIM ANAL YSES 
Interim examination of clinical endpoints and key safety events will be performed at  regular intervals 
during the course of the trial. An independent , NIH -appointed,  DSMB will monitor participant safety and 
review performance of the trial. The primary objective of these interim analyses will be to ensure the 
safety of the participants enr olled in the trial. In addition, interim monitoring will involve a review of 
participant recruitment, compliance with the study protocol, status of data collection, and other factors 
which reflect the overall progress and integrity of the study.  
This proto col does not have  planned early stopping rules for efficacy. Because PASC presentations and 
outcomes are highly varied, an important study objective is to estimate the effect of treatment on a 
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
33 wide range of pa rticipant -relevant outcomes. If the study were to be stopped early with less than the 
full sample size, it would decrease precision and reduce the study's ability to characterize intervention  
risks and benefits based on important secondary effectiveness and safety outcomes. Stopping early  
would also limit the collection of data that are critical for planning future trials in similar patient 
populations.  
 
11 SUPPORTING DOCUMENTATION AND OPERATIONAL  CONSIDERATIONS  
 
11.1 REGULATORY, ETHICA L, AND S TUDY OVERSIGHT CONSIDERATIONS  
 
11.1.1  INFORMED CONSENT PRO CESS 
 
11.1.1.1 INSTITUTIONAL REVIEW  BOARD (IRB)  
The protocol, informed consent form (s) [ICF(s) ], recruitment materials, and all participant materials will 
be submitted to the Institutional Review Board(s) [IRB(s) ] of record for review and approval. This 
approval must be obtained before any participant is enrolled. Any amendment to the protocol will 
require review and approval by the IRB(s) before being implemented in the study. All changes to the consent form will also be IRB- approved and a determination will be made regarding whether previously 
consented participants need to be re -consented. 
11.1.1.2 CONSENT PROCEDURES A ND DOCUMENTATION  
All consenting will occur either via an electronic consent process or a paper process. C onsent forms 
describing in detail the intervention /comparator , study procedures, and risks will be given to the 
participant , and documentation of informed consent is required prior to starting study procedures. 
Informed consent is a process that is initiated prior to the individual’s agreement to participate in the study and continues throughout the individual’s study participation. A description of risks and possible benefits of participation will be provided to the participants. Consent forms will be IRB -approved and 
the participant will be asked to read and review the document. The participant will be provided contact informa tion in the event they have questions about study participation. This will allow them to 
communicate with the investigators (or their delegate), for further explanation of the research study and to answer any questions that may arise, as necessary. Participants will have the opportunity to carefully review the consent form and ask questions prior to signing.  
Participants should have the opportunity to discuss the study and think about it before agreeing to participate. Participants will sign the informed consent document before performing any study procedures. Participants may withdraw consent at any time throughout the course of the study. A copy of the informed consent document will be provided to participants for their records. The rights and 
welfare of p articipants will be protected by emphasizing to them that the quality of their medical care 
will not be adversely affected if they decline to participate in this study.  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
34 The study team will distinguish between the desire to discontinue the intervention and the desire to 
withdraw consent for study follow -up.  
11.1.2  STUDY DISCONTINUATIO N AND CLOSURE  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause . Written notification, documenting the reason for study suspens ion or termination, will be 
provided by the sponsor to study participants, site investigators, the central IRB, and the US FDA , as 
applicable . Study participants will be contacted, as applicable, and be informed of changes to study visit 
schedule. 
Circumst ances that may warrant termination or suspension include, but are not limited to , the 
following : 
• Determination of unexpected, significant, or unacceptable risk to participants  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination that the primary endpoint has been met  
• Determination of futility  
The s tudy may resume once concerns about safety, protocol compliance, and data quality are 
addressed , and satisfy the sponsor, IRB , and/or FDA.  
11.1.3  CONFIDE NTIALITY AND P RIVACY  
Participant confidentiality is strictly held in trust by the participating investigators, their staff, and the 
sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples in addition to the clin ical and private information relating to participants. Therefore, the study protocol, 
documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without 
prior written approval of the sponsor. The study participant’s contact information will be securely stored 
in the clinical study database.  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the CT -DCC. The study data entry and study management systems used 
by clinical sites and by research staff will be secured and password protected. At the end of the study, all study- related data storage systems will be archived according to local processes.  
11.1.4  KEY ROLES  AND STUDY GOVERNANCE  
The RECOVER program is overseen by the RECOVER Executive Committee. The  RECOVER program also 
includes a  Clinical Trial Steering Committee , which  is a multi-stakehol der committee that oversees the 
study and includes patient s, the CT -DCC, the NIH, the FDA, and academic and subject matter experts .  
The CT-DCC is overseen by  a Principal Investigator. The CT -DCC is responsible for study coordination, site 
management, communication, financial administration , treatment allocations, receipt and processing of 
data, quality control programs, and statistical analysis and reporting.  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
35 The DSMB will oversee the safety and welfare of trial participants as well as provide recommendat ions 
for continuation, discontinuation, or revision of the trial.  
11.1.5  DATA AND SAFETY MONI TORING BOARD  
Safety oversight will be under the direction of the RECOVER DSMB composed of individuals with the 
appropriate expertise. Members of the DSMB should be independent from the study conduct and free 
of conflict of interest, or measures should be in place to minimize perceived conflict of interest . The 
DSMB will meet  at least  semi -annually to approve protocols, assess safety and efficacy data , and at 
appropriate intervals to meet requirements for the Interim Analyses on each arm of the study. The DMSB will operate under the rules of an approved charter that will be written and reviewed at the organizational meeting of the DSMB. At this time, eac h data element that the DSMB needs to assess will 
be clearly defined. The DSMB will provide its input to the NIH . 
 
 
11.1.6  CLINICAL MONITORING  
This study will employ a centralized, remote,  risk-based approach to monitoring with routine and 
periodic review of site -submitted data to review  the informed consent process, select eligibility criteria, 
medical history , identify and follow -up on missing data, inconsistent data, data outliers, etc. and ensure 
completion of administrative and regulatory processes.  The study  team will facilitate regular 
communication through training sessions, teleconferences, videoconferencing, email, etc. Using quality -
by-design principles, steps will be taken at the study design stage to foresee and limit significant 
problems that might occur during the study conduct.  
11.1.7  QUALITY ASSURANCE AN D QUALITY CONTROL  
The study team will work in tandem to ensure that the data collected in this study are as complete and 
correct as possible. A four -step, multi -functional approach to quality control will be implemented:  
1. Training . Prior to the start of enrollment, the clinician investigators and key study personnel at 
each site will be trained with the clinical protocol and data collection procedures, including how 
to use the EDC system. Follow -up training and training for new study personnel or new versions 
of the protocol will be conducted as needed.  
 2. Monitoring . The RECOVER CT-DCC will ensure that data collection is handled properly, will 
provide in- service training, and will address questions from site investigators and coordinators. 
Electronic review of data quality and completeness will occur on a regular and ongoing basis. Any issues will be addressed.  
 3. Managing data . After the data have been transferred for statistical summarization, data 
description, and data analysis, further crosschecking of the data will be performed with discrepant observations being flagged and appropriately resolved through a data query system.  
 
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
36 4. Reviewing data . Data regarding events of interest will be reviewed to ensure appropriate 
documents are collected for DSMB review. The CT-DCC will monitor study data  and contact site 
study teams when events comprising the primary endpoint are not complete.  
 
11.1.8  DATA  HANDLING  AND RECORD  KEEPING  
 
11.1.8.1 DATA COLLECTION AND  MANAGEMENT RESPONSIBI LITIES  
Streamlining  research activities and conducting the trial in a pragmatic manner will increase the ability 
to complete the trial in the face of strained clinical and research resources. Data may be collected by 
electronic methods, supplemented by telephone or videophone follow- up, and from the electronic 
health record.  
Data will be collected directly from participants using REDCap through text messaging or email with a 
survey link, or a site -based computer, or phone call as back up. The process for using text messaging and 
email is Health Insurance Portability and Accountability Act (HIPAA) compliant.  
Site personnel or participants will enter study data into a secure online database. Data will be maintained in a secure online database until the time of study publication. At the time of publication, 
the CT-DCC will generate a de -identified version of the database for archiving (see Section 11.1.10).  All 
source documents at the sites should be completed in a neat, legible manner to ensure accurate 
interpretation of data .  
11.1.8.2 STUDY RECORDS RETENT ION 
Study documents should be retained for a minimum of six years  after the study has ended. However, if 
required by local regulations  or the US FDA , these documents should be retained for a longer period. No 
records will be destroyed without the written consent of the sponsor. The sponsor is responsible for informing t he investigator when these documents no longer need to be retained.  
11.1.9  PROTOCOL  DEVIATIONS  
A protocol dev iation is defined as  non-comp liance wi th the  clinical study  protocol or GCP r equirements. 
The non-comp liance may be on the part of the p artici pant , site inv estigator, or the si te staff.  
A major  protocol deviation is a significant divergence from the protocol that may have significant 
effect (s) on the participant’s safety, rights, or welfare and/or on the integrity of the study data. Major 
protocol deviati ons mu st be sent  to th e study IRB and l ocal I RB per their guid elines, recorded in s ource 
docum ents, and r epor ted to the coordinating center. Major protocol deviations will be tracked. For this 
study, any missed or delayed survey completion will not be considered a major protocol deviation , 
unless the survey  is required for the primary endpoint .  
11.1.10  PUBLICATION AND DATA SHARING POLICY  
This study will comply with the NIH Public Access Policy, which ensures that the public has access to the published results of NIH funded research. The Policy requires scientists to submit final peer -reviewed 
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
37 journal manuscripts , which  arise from NIH funds , to the digital archive PubMed Central upon acceptance 
for p ublication. 
11.1.11  CONFLICT OF  INTEREST  POLICY  
The independence of this study from any actual or perceived influence, such as by the pharmaceutical 
industry, is critical . Therefore, any actual conflict of interest of persons who have a role in the design, 
conduct, analysis, publication, or any aspect of this trial must  be disclosed and managed. Furthermore, 
persons who have a perceived conflict of interest will be required to have such conflicts managed in a 
way that is appropriate to their participation in the des ign and conduct of this t rial. The study leadership 
in conjunction with the NIH  has established policies and procedures for all study group members to 
disclose all conflicts of interest and will establish a mechanism for the management of all reported dualities of interest.  
 
 
11.2 ABBREVIATIONS  
 
AE Adverse Event  
ADE Adverse Device Effect  
ADHD  Attention -deficit/hyperactivity disorder  
CDE Common Data Element  
CFR Code of Federal Regulations  
CONSORT  Consolidated Standards of Reporting Trials  
CoRE  Cognitive Recovery  
COVID -19 Coronavirus Disease of 2019  
CRF Case Report Form  
CT-DCC Clinical Trial – Data Coordinating Center  
DCRI  Duke Clinical Research Institute  
DSMB  Data Safety Monitoring Board  
ECog2  Everyday Cognition 2  
eCRF  Electronic Case Report Forms  
EDC Electronic Data Capture  
EOI End of Intervention  
EOS End of Study  
ESI Events of Special Interest  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
ICH International Conference on Harmonisation   
IDE Investigational Device Exemption  
IND Investigational New Drug  
IRB Institutional  Review Board  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
38 ITT Intention -To-Treat  
MOP  Manual of Procedures  
NCT National Clinical Trial  
NIH  National Institutes of Health  
PASC  Post -acute Sequelae of SARS -CoV-2 Infection  
PI Principal Investigator  
PRO  Patient Reported Outcome  
PROMIS  Patient -reported Outcomes Measurement Information System  
PROMIS -Cog PROMIS -Cognitive Function  – short form 8a  
PROMIS -Fatigue  PROMIS -Fatigue – short form 10a  
PROMIS -SD PROMIS -8a Sleep Disturbance  
PROMIS -SRI PROMIS -8a Sleep Related Impairment  
RAVLT  Rey Auditory Verbal Learning Test  
RECOVER  Researching COVID to Enhance Recovery  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SAR Suspected Adverse Reaction  
SARS -CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2  
SMP  Safety Management Plan  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
tDCS  Transcranial Direct Current Stimulation  
UADE  Unanticipated Adverse Device Effect  
US United States  
WHO -UCLA AVLT  World Health Organization -University of California Los Angeles Auditory 
Verbal Learning Test  
 
 
11.3 PROTOCOL  AMENDMENT  HISTORY  
 
Version  Date  Description of Change  
1.0 01MAY2023  None, original protocol  
2.0 09JUN2023  • Added risk posed to participants with post -exertional malaise  
(Section 2.3.1)  
• Replaced the Rey Auditory Verbal Learning Test with the WHO -UCLA 
Verbal Learning Test  (Section 8.9.4.1)  
• Added sub- exclusion to exclusion 12 to convey an investigator has 
discretion to determine whether a participant is too cognitively 
impaired to participate and should be referred for clinical evaluation (Section 5.2)  
• Added rationale for the neurocognitive battery (Section 8.9.4)  
• Changed use of PROMIS 8a SD to 8b SD  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
39 • Added time burden to PASC Symptom Questionnaire  (Section 
8.9.3.4)  
• Added pregnancy requirement for female partners of male 
participants to platform protocol  (Section 9.1.6)  
• Added pregnancy and contraception considerations to Appendix A 
that are different than those in the platform  (Appendix A)  
• Added stool to blood collection  (Section 8.10)  
• Added Subjective Global Assessment Questionnaire at End of 
Intervention  and End of Study  (Section 8.9.3)  
• Defined cognitive training, cognitive -enhancing supplement (Section 
5.3) 
• Added anticholinergics as allowable except within 48 hours of 
assessments (Section 5.3)  
• Added that "Failure to refrain from [benzodiazepine, anticholinergic, 
narcotic] their use in this time frame will require rescheduling of the 
assessments." (Section 5.3)  
• Added concomitant medica tion/therapy review  at MOI (Section 8.1)  
• Changed “control ” to “comparator ” throughout platform  
• Added “±3 Days” to EOS visit  
• Added unanticipated adverse device effects to a secondary outcome  
• Clarified that Clinical laboratory assessments will not be required as 
part of Baseline assessments. (Section 13.4.5)  
• Added twice weekly DSQ -PEM assessments throughout the 
intervention (Section 8.1)  
• Other administrative changes, such as grammar and punctuation  
3.0 10JAN2024  • Added NCT numbers to the cover page for  the platform protocol and 
to Appendix A  
• Edited the primary endpoint from change in total score to change in 
average score  (Section 3)  
• Added the exclusion of ADHD diagnosis treated with stimulants that 
cannot be discontinued (Section 5.2)  
• Added the exclusi on of lifetime use of electroconvulsive therapy  
(Section 5.2)   
• Edited exclusion # 4 to direct the reader to pro hibited medications in 
Table 2  (Section 5.2)  
• Added a footnote to exclusion #4 that allows for a washout period of prohibited medications (Section 5.2)  
• Edited exclusion # 6 from any stimula nt treating PASC to any 
medication treating PASC  (Section 5.2)  
• Added Table 2 for prohibited medications  and thera pies 
• Edited section 6.4.1 to be for prohibited medications  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
40 • Added a 30 -day washout requirement for participants who stop 
taking a cognitive -enhancing supplement before being enrolled 
(Section 5.3)  
• Moved and edited language from Section 5.3 about occasional use of 
drugs to Section 6.4.1 with Table 2  
• Added 21- day buffer to Start of Intervention due the potential time 
required for forming PASC -CoRE groups (Section 8.1)  
• Added blood pressure and heart rate collection to the Baseline , EOI, 
and EOS  visits (Section 8.1)Added that participants cannot change 
their  stimulant dose while on- study (Section 5.3)  
• Added that 90 days must lapse after completing another trial before screening for this one (Section 5.6)  
• Added statements to clarify randomization (Section 6.2)  
• Added alternative therapy instructions (Section 6.4.2)  
• Removed that participants may be replaced (Section 7.1)  
• Added that “Participants who fail screening may be re -screened one 
time .” (Section 8.2)  
• Separated COVID treatment from medical history and moved COV ID 
treatment to Baseline (Section 8.3)  
• Made the term “cognitive dysfunction” consistent throughout  
• Edited the look -back periods for the DSQ -PEM (Section 8.9.3.5)  
• Rey Auditory Verbal Learning Test added as an AVLT with the WHO -
UCLA AVLT, with corresponding changes  made throughout (Section 
8.9.4.1)  
• Added that pregnancy testing is not required for female participants who self -report menopause, have no menstrual cycle for at least 12 
months, or are surgically sterile  (Section 13.7)  
• Added pregnancy considerations to Appendix A (Section 13.7)  
• Updated the primary comparisons in Appendix A (Section 13.8.2)  
• Made punctuation changes  throughout  
 
12 REFERENCES  
1. Cabrera Martimbianco AL, Pacheco RL, Bagattini Â M, Riera R. Frequency, signs and symptoms, and 
criteria adopted for long COVID -19: A systematic review. Int J Clin Pract . Oct 2021;75(10):e14357. 
doi:10.1111/ijcp.14357  
2. Huang C, Huang L, Wang Y, et al. 6 -month consequences of COVID -19 in patients discharged from 
hospital: a cohort study. Lancet . Jan 16 2021;397(10270):220 -232. doi:10.1016/s0140- 6736(20)32656-8 
3. Hirschtick JL, Titus AR, Slocum E, et al. Population -Based Estimates of Post -acute Sequelae of Severe Acute 
Respiratory Syndrome Coronavirus 2 (SARS -CoV-2) Infection (PASC) Prevalence and Characteristics. Clin Infect Dis. 
Dec 6 2021;73(11):2055- 2064. doi:10.1093/cid/ciab408  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
41 4. Bell ML, Catalfamo CJ, Farland LV, et  al. Post -acute sequelae of COVID -19 in a non -hospitalized cohort: 
Results from the Arizona CoVHORT. PLoS One . 2021;16(8):e0254347. doi:10.1371/journal.pone.0254347  
5. Woo MS, Malsy J, Pottgen J, et al. Frequent neurocognitive deficits after recovery from mild COVID -19. 
Brain Commun . 2020;2(2):fcaa205. doi:10.1093/braincomms/fcaa205  
6. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of 
symptoms and their impact. EClinicalMedicine . Aug 2021;38:101019. do i:10.1016/j.eclinm.2021.101019  
7. Zhu N ZD, Wang W. A Novel Coronavirus from Patients with Pneumonia in China. N Engl J Med 
2020;382:727- 733.  
8. Goodman BP, Khoury JA, Blair JE, Grill MF. COVID -19 Dysautonomia. Front Neurol . 2021;12:624968. 
doi:10.3389/fn eur.2021.624968  
9. Barizien N, Le Guen M, Russel S, Touche P, Huang F, Vallée A. Clinical characterization of dysautonomia in 
long COVID -19 patients. Sci Rep . Jul 7 2021;11(1):14042. doi:10.1038/s41598 -021- 93546- 5 
10. Klein R, Soung A, Sissoko C, et al. CO VID-19 induces neuroinflammation and loss of hippocampal 
neurogenesis. Res Sq . Oct 29 2021;doi:10.21203/rs.3.rs -1031824/v1  
11. Stefano GB, Buttiker P, Weissenberger S, Martin A, Ptacek R, Kream RM. Editorial: The Pathogenesis of 
Long -Term Neuropsychiatric COVID -19 and the Role of Microglia, Mitochondria, and Persistent 
Neuroinflammation: A Hypothesis. Med Sci Monit . May 10 2021;27:e933015. doi:10.12659/MSM.933015  
12. Nalbandian A, Sehgal K, Gupta A, et al. Post -acute COVID -19 syndrome. Nature Medicine . 2021/04/01 
2021;27(4):601 -615. doi:10.1038/s41591 -021- 01283- z 
13. Carfi A, Bernabei R, Landi F, Gemelli Against C -P-ACSG. Persistent Symptoms in Patients After Acute 
COVID -19. JAMA. Aug 11 2020;324(6):603- 605. doi:10.1001/jama.2020.12603  
14. Mantovani E, Mario tto S, Gabbiani D, et al. Chronic fatigue syndrome: an emerging sequela in COVID -19 
survivors? J Neurovirol . Aug 2021;27(4):631- 637. doi:10.1007/s13365- 021- 01002- x 
15. Bierle DM, Aakre CA, Grach SL, Salonen BR, Croghan IT, Hurt RT, Ganesh R. Central Sensit ization 
Phenotypes in Post Acute Sequelae of SARS -CoV-2 Infection (PASC): Defining the Post COVID Syndrome. J Prim 
Care Community Health. Jan -Dec 2021;12:21501327211030826. doi:10.1177/21501327211030826  
16. Valle A, Roizenblatt S, Botte S, et al. Efficacy of anodal transcranial direct current stimulation (tDCS) for 
the treatment of fibromyalgia: results of a randomized, sham -controlled longitudinal clinical trial. J Pain Manag. 
2009;2(3):353- 361.  
17. Przeklasa -Muszynska A, Kocot -Kepska M, Dobrogowski J, Wi atr M, Mika J. Transcranial direct current 
stimulation (tDCS) and its influence on analgesics effectiveness in patients suffering from migraine headache. 
Pharmacol Rep . Aug 2017;69(4):714- 721. doi:10.1016/j.pharep.2017.02.019  
18. Renaud- Charest O, Lui LMW,  Eskander S, et al. Onset and frequency of depression in post -COVID -19 
syndrome: A systematic review. Journal of Psychiatric Research. 2021/12/01/ 2021;144:129 -137. 
doi:https://doi.org/10.101 6/j.jpsychires.2021.09.054  
19. Lorkiewicz P, Waszkiewicz N. Biomarkers of Post -COVID Depression. J Clin Med . Sep 14 
2021;10(18)doi:10.3390/jcm10184142  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
42 20. Alonzo A, Fong J, Ball N, Martin D, Chand N, Loo C. Pilot trial of home -administered transcranial direct 
current stimulation for the treatment of depression. J Affect Disord . Jun 1 2019;252:475 -483. 
doi:10.1016/j.jad.2019.04.041  
21. Brunoni AR, Boggio PS, De Raedt R, et al. Cognitive control therapy and transcranial direct current 
stimulation for depression: a randomized, double -blinded, controlled trial. J Affect Disord . Jun 2014;162:43- 9. 
doi:10.1016/j.jad.2014.03.026  
22. D'Urso G, Dell'Osso B, Rossi R, e t al. Clinical predictors of acute response to transcranial direct current 
stimulation (tDCS) in major depression. J Affect Disord . Sep 2017;219:25- 30. doi:10.1016/j.jad.2017.05.019  
23. D'Urso G, Mantovani A, Patti S, Toscano E, de Bartolomeis A. Transcran ial Direct Current Stimulation in 
Obsessive -Compulsive Disorder, Posttraumatic Stress Disorder, and Anxiety Disorders. J ECT . Sep 2018;34(3):172-
181. doi:10.1097/YCT.0000000000000538  
24. de Lima AL, Braga FMA, da Costa RMM, Gomes EP, Brunoni AR, Pegado R. Transcranial direct current 
stimulation for the treatment of generalized anxiety disorder: A randomized clinical trial. J Affect Disord . Dec 1 
2019;259:31- 37. doi:10.1016/j.jad.2019.08.020  
25. Even Mild Cases Can Cause “COVID -19 Fog”. Accessed December 8, 2022. 
https://www.cuimc.columbia.edu/news/even- mild -cases- can-cause -covid -19-fog 
26. Liu YH, Chen Y, Wang QH, et al. One -Year Trajectory of Cognitive Changes in Olde r Survivors of COVID -19 
in Wuhan, China: A Longitudinal Cohort Study. JAMA Neurol . May 1 2022;79(5):509- 517. 
doi:10.1001/jamaneurol.2022.0461  
27. Becker JH, Lin JJ, Doernberg M, Stone K, Navis A, Festa JR, Wisnivesky JP. Assessment of Cognitive 
Function in Patients After COVID- 19 Infection. JAMA Netw Open . Oct 1 2021;4(10):e2130645. 
doi:10.1001/jamanetworkopen.2021.30645  
28. Barrios H, Narciso S, Guerreiro M, Maroco J, Logsdon R, de Mendonca A. Quality of life in patients with 
mild cognitive impairment. Aging Ment Health. 2013;17(3):287- 92. doi:10.1080/13607863.2012.747083  
29. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long -term cognitive impairment and functional disability 
among survivors of severe sepsis. JAMA. Oct 27 2010;304(16):1787- 94. doi:10.1001/jama. 2010.1553 
30. Donovan NJ, Wu Q, Rentz DM, Sperling RA, Marshall GA, Glymour MM. Loneliness, depression and 
cognitive function in older U.S. adults. Int J Geriatr Psychiatry . May 2017;32(5):564- 573. doi:10.1002/gps.4495  
31. Mazza MG, Palladini M, De Lorenzo R, et al. Persistent psychopathology and neurocognitive impairment in 
COVID -19 survivors: Effect of inflammatory biomarkers at three -month follow -up. Brain Behav Immun. May 
2021;94:138- 147. doi:10.1016/j.bbi.2021.02.021  
32. De Luca P, Camaioni A, Marra P, et al. Effect of Ultra- Micronized Palmitoylethanolamide and Luteolin on 
Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study. Cells. Aug 17 
2022;11(16)doi:10.3390/cells11162552  
33. Cheshire WP,  Freeman R, Gibbons CH, et al. Electrodiagnostic assessment of the autonomic nervous 
system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. Clin  Neurophysiol . Feb 2021;132(2):666- 682. 
doi:10.1016/j.clinph.2020.11.024  
34. Case definitions for COVID -19 surveillance. Pan American Health Organization. Accessed October 15, 
2022. https://www.paho.org/en/case -definitions- covid -19-surveillance  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
43 35. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post -COVID -19 condition by 
a Delphi consensus. Lancet Infect Dis . Apr 2022;22(4):e102- e107. doi:10.1016/s1473 -3099(21)00703 -9 
36. Farias SET, Mungas D, Reed BR, Cahn -Weiner DA, Jagust WJ, Baynes K, DeCarli C. The measurement of 
everyday cognition (ECog): scale development and psychometric properties. Neuropsychology . 2008;22 4:531 -44.  
37. Rodakowski J, G olias KW, Reynolds CF, 3rd, Butters MA, Lopez OL, Dew MA, Skidmore ER. Preventing 
disability in older adults with mild cognitive impairment: A Strategy Training intervention study. Contemp Clin 
Trials Commun . Sep 2019;15:100368. doi:10.1016/j.conctc.2019.100368  
38. McCombe N, Ding X, Prasad G, et al. Alzheimer's Disease Assessments Optimized for Diagnostic Accuracy 
and Administration Time. IEEE J Transl Eng Health Med. 2022;10:4900809. doi:10.1109/jtehm.2022.3164806  
39. Mace RA, Hopkins SW, Reynolds GO, Vra nceanu AM. My Healthy Brain: Rationale and Case Report of a 
Virtual Group Lifestyle Program Targeting Modifiable Risk Factors for Dementia. J Clin Psychol Med Settings . Dec 
2022;29(4):818 -830. doi:10.1007/s10880 -022- 09843- 2 
40. Cella D, Yount S, Rothrock N, et al. The Patient -Reported Outcomes Measurement Information System 
(PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care . May 2007;45(5 
Suppl 1):S3 -S11. doi:10.1097/01.mlr.0000258615.4247 8.55  
41. Iverson GL, Marsh JM, Connors EJ, Terry DP. Normative Reference Values, Reliability, and Item -Level 
Symptom Endorsement for the PROMIS® v2.0 Cognitive Function -Short Forms 4a, 6a and 8a. Arch Clin 
Neuropsychol . Oct 13 2021;36(7):1341- 1349. doi:10. 1093/arclin/acaa128  
42. Cella D, Yount S, Rothrock N, et al. The Patient -Reported Outcomes Measurement Information System 
(PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care . May 2007;45(5 
Suppl 1):S3 -s11. doi:10.1097/01.mlr.0000258615.42478.55  
43. Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary 
scores from the patient -reported outcomes measurement information system (PROMIS) global items. Qual Life 
Res. Sep 2009;18(7):873 -80. doi:10.1007/s11136- 009- 9496- 9 
44. Ganesh R, Ghosh AK, Nyman MA, et al. PROMIS Scales for Assessment of Persistent Post -COVID 
Symptoms: A Cross Sectional Study. J Prim Care Community Health. Jan -Dec 2021;12:21501327211030413. 
doi:10.1177/21501327211030413  
45. Ameringer S, Elswick RK, Jr., Menzies V, et al. Psychometric Evaluation of the Patient -Reported Outcomes 
Measurement Information System Fatigue -Short Form Across Diverse Populations. Nurs Res . Jul-Aug 
2016;65(4):279 -89. doi:10.1097/nnr.0000000000000162  
46. Cotler J, Holtzman C, Dudun C, Jason LA. A Brief Questionnaire to Assess Post -Exertional Malaise. 
Diagnostics (Basel) . Sep 11 2018;8(3)doi:10.3390/diagnostics8030066  
47. Geffen GM, Butterworth P, Geffen LB. Test -retest reliability of a new form of the auditory verbal learning 
test (AVLT). Arch Clin Neuropsychol . Jul 1994;9(4):303- 16.  
48. Miranda JP, Valencia RR. English and Spanish versions of a memory test: Word -length effects versus 
spoken -duration effects. Hispanic Journal of Behavio ral Sciences. May 1997;19(2):171- 181. doi:Doi 
10.1177/07399863970192005  
49. Maj M, D'Elia L, Satz P, et al. Evaluation of two new neuropsychological tests designed to minimize 
cultural bias in the assessment of HIV -1 seropositive persons: a WHO study. Arch  Clin Neuropsychol . Mar 
1993;8(2):123- 35.  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
44 50. Alviarez -Schulze V, Cattaneo G, Pachon -Garcia C, Solana- Sanchez J, Tormos JM, Pascual -Leone A, Bartres -
Faz D. Validation and Normative Data of the Spanish Version of the Rey Auditory Verbal Learning Test and 
Associated Long -Term Forgetting Measures in Middle -Aged Adults. Front Aging Neurosci . 2022;14:809019. 
doi:10.3389/fnagi.2022.809019  
51. Smith A. Symbol digit modalities test . Western psychological services Los Angeles; 1973.  
52. Besser L, Kukull W, Knopman DS, et al. Version 3 of the National Alzheimer's Coordinating Center's 
Uniform Data Set. Alzheimer Dis Assoc Disord . Oct -Dec 2018;32(4):351- 358. doi:10.1097/wad.0000000000000279  
53. Kelland DZ, Lewis RF. The digit vigilance test: reliability, validity, and  sensitivity to diazepam. Archives of 
Clinical Neuropsychology . 1996/01/01/ 1996;11(4):339 -344. doi: https://doi.org/10.1016/0887 -6177(95)00032- 1 
54. Cogstate. Digital Cognitive Assessment. Accessed November 28, 2022. https://www.cogstate.com/clinical -
trials/digital- cognitive -assessment/   
55. Edgar CJ, Siemers E, Maruff P, Petersen RC, Aisen PS, Weiner MW, Albala  B. Pilot Evaluation of the 
Unsupervised, At -Home Cogstate Brief Battery in ADNI -2. J Alzheimers Dis. 2021;83(2):915- 925. doi:10.3233/jad -
210201  
56. Maruff P, Thomas E, Cysique L, Brew B, Collie A, Snyder P, Pietrzak RH. Validity of the CogState brief 
battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, 
schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol . Mar 2009;24(2):165- 78. 
doi:10.1093/arclin/acp010  
57. Zelazo PD, Anderson JE, R ichler J, et al. NIH Toolbox Cognition Battery (CB): validation of executive 
function measures in adults. J Int Neuropsychol Soc . Jul 2014;20(6):620 -9. doi:10.1017/S1355617714000472  
58. Proschan MA, Waclawiw MA. Practical guidelines for multiplicity adjustment in clinical trials. Control Clin 
Trials. Dec 2000;21(6):527- 39. doi:10.1016/s0197 -2456(00)00106- 9 
59. Turner GR, Novakovic -Agopian T, Kornblith E, Adnan A, Madore M, Chen AJW, D'Esp osito M. Goal -
Oriented Attention Self- Regulation (GOALS) training in older adults. Aging Ment Health. Mar 2020;24(3):464 -473. 
doi:10.1080/13607863.2018.1534080  
60. Novakovic -Agopian T, Posecion L, Kornblith E, et al. Goal- Oriented Attention Self- Regulation Training 
Improves Executive Functioning in Veterans with Post -Traumatic Stress Disorder and Mild Traumatic Brain Injury. J 
Neurotrauma . Mar 2021;38(5):582- 592. doi :10.1089/neu.2019.6806  
61. Loya F, Novakovic -Agopian T, Binder D, Rossi A, Rome S, Murphy M, Chen AJ. Long -Term Use and 
Perceived Benefits of Goal -Oriented Attentional Self -Regulation Training in Chronic Brain Injury. Rehabil Res Pract . 
2017;2017:8379347. doi:10.1155/2017/8379347  
62. Adnan A, Chen AJW, Novakovic -Agopian T, D'Esposito M, Turner GR. Brain Changes Following Executive 
Control Training in Older Adults. Neurorehabil Neural Repair . Oct -Nov 2017;31(10 -11):910- 922. 
doi:10.1177/1545968317728580  
63. Pilloni G, Vogel- Eyny A, Lustberg M, et al. Tolerability and feasibility of at -home remotely supervised 
transcranial direct current stimulation (RS -tDCS): Single -center evidence from 6,779 sessions. Brain Stimul . May -
Jun 2022;15(3):707 -716. doi:10.1016/j.br s.2022.04.014  
64. Pilloni G, Woods AJ, Charvet L. No risk of skin lesion or burn with transcranial direct current stimulation 
(tDCS) using standardized protocols. Brain Stimul . May -Jun 2021;14(3):511- 512. doi:10.1016/j.brs.2021.03.006  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
45 65. Muccio M, Walton Masters L, Pilloni G, et al. Cerebral metabolic rate of oxygen (CMRO(2)) changes 
measured with simultaneous tDCS -MRI in healthy adults. Brain Res . Dec 1 2022;1796:148097. 
doi:10.1016/j.brainres.2022.148097  
66. Choi C. Transcranial Direct Current Stimulatio n (TDCS) Induces Acute Changes in Brain Metabolism. AAN 
Enterprises. 2019;(S33.004)  
67. Choe J, Coffman BA, Bergstedt DT, Ziegler MD, Phillips ME. Transcranial Direct Current Stimulation 
Modulates Neuronal Activity and Learning in Pilot Training. Front Hum  Neurosci. 2016;10:34. 
doi:10.3389/fnhum.2016.00034  
68. Brunoni AR, Vanderhasselt MA. Working memory improvement with non -invasive brain stimulation of the 
dorsolateral prefrontal cortex: a systematic review and meta -analysis. Brain Cogn. Apr 2014;86:1 -9. 
doi:10.1016/j.bandc.2014.01.008  
69. McIntire LK, McKinley RA, Goodyear C, Nelson J. A comparison of the effects of transcranial direct current 
stimulation and caffeine on vigilance and cognitive performance during extended wakefulness. Brain Stimul . Jul-
Aug 2014;7(4):499 -507. doi:10.1016/j.brs.2014.04.008  
70. Elmasry J, Loo C, Martin D. A systematic review of transcranial electrical stimulation combined with 
cognitive training. Restor Neurol Neurosci . 2015;33(3):263 -78. doi:10.3233/RNN -140473  
71. Gill J, Sh ah-Basak PP, Hamilton R. It's the thought that counts: examining the task- dependent effects of 
transcranial direct current stimulation on executive function. Brain Stimul . Mar -Apr 2015;8(2):253 -9. 
doi:10.1016/j.brs.2014.10.018  
72. Charvet L. Cognitive Func tioning in MS Improves with At - Home Online Training Paired with Transcranial 
Direct Current Stimulation (tDCS): Results f rom a Sham -Controlled Randomized Clinical Trial. ACTRIMS. 
https://www.abstractsonline.com/pp8/#!/10495/presentation/67  
73. Smith GE, Housen P, Yaffe K, Ruff R, Kennison RF, Mahncke HW, Zelinski EM. A cognitive training program 
based on principles of brain plasticity: results from the Improvement in Memory with Plasticity -based Adaptive 
Cognitive Training (IMPACT) study. J Am Geriatr Soc . Apr 2009;57(4):594- 603. doi:10.1111/j.1532-
5415.2008.02167.x  
74. Bikson M, Grossman P, Thomas C, et al. Safety of Transcranial Direct Current Stimulation: Evidence Based 
Update 2016. Brain Stimul . Sep -Oct 2016;9(5):641 -661. doi:10.1016/j.brs.2016.06.004  
75. Novakovic -Agopian T, Kornblith E, Abrams G, Burciaga -Rosales J, Loya F, D'Esposito M, Chen AJW. Training 
in Goal -Oriented Attention Self -Regulation Improves Executive Functioning in Veterans with Chronic Traumatic 
Brain Injury. J Neurotrauma. Dec 1 2018;35(23):2784- 2795. doi:10.1089/neu.2017.5529  
 
  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
46 13 APPENDIX A  
 
This intervention is registered on clinicaltrials.gov as [STUDY_ID_REMOVED].  
 
13.1 INTERVENTION  RATIONALE  
The interventions  below comprise this appendix.  
13.1.1  BRAINHQ  
BrainHQ is an online cognitive training program developed by Posit Science Corporation, and has been 
used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity. It targets memory, attention, and brain speed. BrainHQ has 29 training exercises and a 
total of 800 training levels. Exercises focus on speed and accuracy of neural information processing with a reward system when exercises are performed correc tly. BrainHQ is a fully remote training system 
delivered through an application  on an electronic device, such as a tablet or computer.  
BrainHQ is established for research use and has been used in brain- injured populations. It  provides a 
portal that resear ch teams can use to specialize the challenges  that are presented to participants. 
BrainHQ continuously challenges participants by using algorithms that adapt to each participant’s initial cognitive impairment and learning rate. Moreover, BrainHQ exercises are visually appealing and responsive in order to maintain user engagement.  
BrainHQ platform provides  a set of cognitive activities, like puzzles and games, that are cognitively 
stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities  are designed to be a face -valid , active comparison approach to cognitive therapy, thus 
participants are blinded, attention time is matched, and overall user experience is identical to the active arms.  
13.1.2  PASC -COGNITIVE RECOVERY  
PASC -Cognitive Recovery (PASC -CoRE)  is a manualized cognitive rehabilitation intervention with 
demonstrated efficacy in improving attention and executive functions, among other cognitive domains.
59-61 PASC -CoRE  comprises 3 essential  training components: 1) attention regulation using a 
mindfulness -based approach; 2) training in goal management; and 3) managing cognitive fatigue.  
Attention regulation training uses mindfulness to emphasize redirect ion of  cognitive processes towards 
tasks that are salient . Participants are taught to use these principles in a range of personally relevant 
situations. Training takes place virtually through one -on-one or group sessions. Additionally, homework 
is assigned for more practice in applying these attention- regulation principles.  Goal management 
training encourages  participants to identify, select, and execute self -generated, personally rele vant, and 
functional goals.  
Fatigue management training teaches participants strategies for managing cognitive fatigue, including “brain breaks,” planning ahead, and avoiding overstimulation.  
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
47 PASC -CoRE  is cognitive rehabilitation targeting improvements in executive function and attention. It is a 
therapy based on an understanding of brain- behavior relationships and may  even  be capable of inducing 
neuroplasticity- related brain changes.62  
13.1.3  TRANSCRAN IAL DIRECT CURRENT S TIMULATION  
Transcranial direct current stimulation ( tDCS ) will use  a device developed by Soterix Medical, Inc. 
specifically for home -based use (Soterix 1x1 mini -CT). Th is device deliver s a weak electrical current of 
2.0 mA passed through two electrodes placed on the scalp to target  the dorsolateral prefrontal cortex  
region of the brain. The electrodes are single- use for each session and can be attached to a headset by 
snapping into place.   
The device has a user -friendly interface and a large -button keypad, making it is easy to use at home. It 
has many built -in safety features, and the user can easily abort any session if needed. tDCS is FDA -
approved for  investigational use in the US  and has an excellent safety and tolerability profile (i.e., no 
serious AE reported in human clinical trials to date).63,64 
tDCS has demonstrated efficacy for many symptoms in the neuropsychiatric cluster, including cognitive 
dysfunction, central fatigue, central sensitization, and emotional dysregulation. Possible mechanisms of tDCS include increases in neuronal activity and blood flow.
65,66 When paired with a cognitive training 
activity, it  may potentiate  and strengthen the learning process.67 tDCS targeted to brain regions engaged 
in the cognitive t raining activity increases brain activity and the corresponding rate of learning during 
training, thus enhancing its therapeutic outcomes. Pairing with cognitive training may increase  learning 
and performance outcomes, and targeting the dorsolateral prefro ntal cortex may lead  specifically to  
improvement in measures of processing speed.68-71 Repeated application of tDCS has been reported to 
improve  cognitive function.72  
13.2 EXCLUSION CRITERIA (APPENDIX LEVEL)  
 
1. Presence of metal objects in the head or neck  
2. Skin disorders or skin -sensitive areas near tDCS stimulation locations that would interfere with 
electrode placement or increase the risk of stimulation -induced damage, at the investigator’s 
discretion  
13.3 STUDY DESIGN  
These interventions will comprise a five -arm design implemented over 10 weeks :   
1. Active Comparator  (video games)  
2. BrainHQ  
3. BrainHQ + PASC -CoRE  
4. BrainHQ + tDCS -active  
5. BrainHQ + tDCS -sham  
 
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
48 13.3.1  DESIGN RATIONALE  
This design seeks to evaluate each intervention r elative to the Active Comparator . The BrainHQ (alone) 
arm is important because the intervention is commercially available, accessible, relatively inexpensive, 
and does not require trained personnel to administer. The BrainHQ + PASC -CoRE  arm and the BrainHQ  + 
tDCS arm s are suspected to provide cognitive improvements beyond BrainHQ alone through different 
mechanisms.  Both PASC -CoRE  and tDCS have extensive prior use.  This design does not control for PASC -
CoRE ; doing so would require a second control group, which would reduce power for observing 
differences among the primary comparisons. Further, this design positively compromises study -design 
purity for reduced patient burden and affords analysis of  incremental value of intervention  
combinations most likely to be implemented clinically.  
This study design is unique compared to other ongoing or forthcoming clinical trials : It is the only trial 
investigating BrainHQ alone or BrainHQ paired with PASC -CoRE  in a PASC population. Conversely, this 
study uniquely compl ements three trials that are or will be recruiting to investigate tDCS with or without 
cognitive training in patients with PASC. Table 3 summarizes thes e studies primary outcomes and 
interventions.  
Table 4. Comparison studies for Appendix A  
 
Abbreviations: tDCS, transcranial direct current stimulation; CT, cognitive training  
This study complements those in Table 3 because it is investigating BrainHQ alone and is dosing tDCS for 
a longer duration and session time, while using the same intensity. Further, this study is  evaluating 
neuropsychological changes, though in a larger population. Together, these studies will offer observations on the efficacy of tDCS, particularly tDCS combined with cognitive training, on enhancing cognitive domains in the PASC population.  
13.3.2  RANDOMIZATION  
Participants will be randomized equally across the five arms, i.e., the randomization probability will be 
0.2 for each arm .  
 
 NCT# Status Primary Outcome I ntervention Arms tDCS DoseEstimated 
Enrollment
5092516 Recruiting Change in inhibitory control 
and processing speedtDCS-active
tDCS-sham 2.0 mA, 4 wk, 7 d/wk, 30 min/d 4 0
5589272 Not yet 
recruitingChange in working memory tDCS-active + CT (4 wk)
tDCS-sham + CT (4 wk)
tDCS-active + CT (5d)
t
DCS-sham + CT (5d)4 wk: 2.0 mA, 4 wk, 4 d/wk, 20 min/d
5 d: 2.0 mA, 5 d consecutive, 13 min/d60
5389592 Not yet 
recruitingChange in neuropsychological 
assessments of memory, 
attention, executive functions, 
a
nd moodtDCS-active + CT (BrainHQ)
tDCS-sham + CT (BrainHQ)2.0 mA, 4 wk, 5 d/wk, 20 min/d 60
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
49 13.3.3  BLINDING  
Participants, investigators, study personnel, and analysts will be blinded to whether participants are in 
(a) the BrainHQ or Active Comparator  arms and (b) the BrainHQ + tDCS -active and BrainHQ + tDCS -sham 
arms.  
13.3.4  SCHEMA  
Figure 2. Schematic of Appendix A intervention  
 
13.3.5  CONTROL/COMPARATOR  
The control group is an active comparison group, i.e., not inactive like a waitlist control. The Active 
Comparator group will receive non -adaptive training or video games, such as word puzzles and visual 
search games, delivered through the same BrainHQ research portal.  
13.4 INTERVENTION PROCEDU RES 
All intervention procedures will be performed remotely, which requires accessing a device with internet 
connection. However, limited technology access will not preclude participation. All participants will receive an electronic device  preloaded with the relevant BrainHQ configuration and videoconferencing 
software. Participants without internet access will be provided a hotspot. Additionally, participants in 
the tDCS groups will be mailed the necessary hardware (see Section 13.4.3). After the intervention , 
participants will return all materials .  
13.4.1  BRAINHQ  
BrainHQ and Active Comparator  sessions will number 50 over the 10- week perio d at 5 sessions/week 
and 30 min/session. In each of the four active intervention  arms using BrainHQ, participants will receive 
active cognitive training . The BrainHQ research portal will be configured for the active cognitive training 
condition (BrainHQ ar ms), or the control cognitive training condition ( Active Compar ator arm) , in 
advance of delivering the device to participants .  

RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
50 Before and after each BrainHQ or Active Compar ator session, participants will be prompted to complete 
a questionnaire, which will document session completion and highlight session interruptions.  
Participants will be monitored by a study technician during the entirety of the first 3 sessions. Afterward, 
participants will be briefly monitored , at startup and the initial few minute s. 
13.4.2  PASC -COGNITIVE RECOV ERY  
PASC -CoRE  components will be delivered by trained interventionists during weekly virtual sessions, 
totaling  nine 1.5- hour group sessions and three 30- minute  individual sessions  (see Table 4 for session 
content) . Individual sessions will occur at the beginning, middle, and end of training series to allow for 
group session review and one -on-one pa rticipant  feedback. Group sessions will include two to five 
participants and one interventionist. The small groups will empower participants to be more active and afford easier scheduling. All sessions will be scheduled to maximize convenience for participants, and will include evenings and weekends. Fu rther, participants will only be required to move through the 
sessions by scheduled sequence, but they will not be restricted to the same group of participants.  
A training manual divided by session will be mailed to participants , who  will be instructed to open each 
session -specific manual at the beginning of the relevant session by the session interventionist . 
Participants will receive an overview of materials and training in Session #1 .  
Table 5. PASC -CoRE  session content  
Session  Content  
Group #1  Introduction and overview  
Group #2  Progressive information maintenance and mindfulness exercises  
Individual #1  Individualized assessment and strategy building 
Group #3  Goal selection: options for group and individual projects  
Group #4  Breaking down projects into sub- tasks, creating timeline; apply to group and individual projects  
Group #5  Execution and dealing with procrastination  
Individual #2  Individualized progress monitoring  
Group #6  Staying on tasks , error correction, and adjustments  
Group #7  Project progress review and adjustments  
Group #8  Individual project presentation  
Group #9  Group project presentation, discussion of maintenance, and graduation celebration  
Individual #3  Individual wrap- up 
 
13.4.3  TRANSCRANIAL DIRECT CURRENT STIMULATION  
tDCS devices, headgear, and electrodes  displayed in Figure 3  will be mailed directly to participants.  tDCS 
devices used in the active arm will be pre -programmed to deliver the direct electrical current at 2.0 mA 
for 30 minutes. tDCS devices used in the sham arm will be pre -programmed to deliver the same ramp 
up/down at the beginning/end of the 30- minute period as the active arm, except with no current 
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
51 otherwise delivered during the session. For both arms, time of day and consistency of electrode 
placement will b e held as constant as possible; however, given the real -world nature of this study, 
flexibility will be a llow ed. 
To begin each live online session, a study technician will check for safety and visually confirm correct 
headset placement and adequate contact quality. Then, the study technician will confirm that the 
participant is ready to start the session and guide the participant to unlock the device using the one -
time use unlock code . At the end of each session, participants will dispose of the single -use electrodes.  
The study technician will monitor the entire tDCS session for compliance at  each daily session during the 
first week; thereafter, only one session per week  will be entirely monitored , while the other four will be  
briefly monitored for headset placement and contact quality .  
tDCS use will be paired with BrainHQ engagement. Partici pants will engage BrainHQ and then position 
and power on the headgear. After 30 minutes, participants will disengage from BrainHQ and remove the 
headgear.  
After the intervention, participants will return the devices and headgear in a prepaid container tha t 
came with the original package .  
Figure 3. Equipment for tDCS intervention   
 
(A) 1x1 Mini -CT tDCS device; (B) SNAPstrap Headgear; (C) EASYpad Electrodes.  
13.4.4  DOSING  
In summary, the dosing of these intervention arms are as follows:  
• Active Compar ator: 5 sessions/week at 30 min/session  
• BrainHQ: 5 sessions/week at 30 min/session  
• BrainHQ + PASC -CoRE : BrainHQ plus 9 group sessions at 1.5 hr/session and 3 individual sessions 
at 30 min/session  
• BrainHQ + tDCS -active: 2.0 mA stimulation delivered for 30 min during each BrainHQ session 
• BrainHQ + tDCS -sham: inactive stimulation delivered for 30 min during each BrainHQ session 
13.4.5  SCHEDULE OF PROCEDUR ES (APPENDIX -LEVEL DIFFERENCES)  

RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
52 Clinical laboratory assessments will not be required  as part of Basel ine assessments, in contrast to 
Section 8.8.  
13.4.6  ADHERENCE 
High adherence is expected given the remote nature of the intervention and the study team -participant 
engagement. Further, tDCS sessions will be monitored regularly; adherence will be captured by the 
device per session completion . Moreover, the study’s cloud database will alert  participants when they 
are to complete their daily session. Finally, the study team will provide remote computer support and 
technical assistance to ease an y technical barriers participants may encounter. Although, participants 
are encouraged to complete every BrainHQ and tDCS session, one 3- day pause is allowed and will not 
trigger non- adherence.  
13.5 SAFETY  
BrainHQ and PASC -CoRE  have no obvious risks and have been designated non- significant risk  devices by 
the FDA . Minor AEs associated with BrainHQ are wrist soreness and headache.73  
tDCS has also been designated  non- significant risk with no known risk of SAEs , though common side 
effects include warmth, itching, or tingling under the electrodes. tDCS will be  remotely supervised and 
within safety limits established by previous research. The tDCS device affords dose  and usage control by 
employing a one -time use -code provided by the study team to unlock the device for each stimulation 
session  (i.e., the device cannot be used outside this window) . Additional built -in safety features  include  
automatic shutoff and a manual abort button. Furthermore, the study team trains participants on 
headgear placement and overall device use.  Importantly, tDCS  poses no risk of worsening headache in 
patients with migraines and is not associated with seizure activity in patients with epi lepsy.74  
13.6 EVENTS OF SPECIAL IN TEREST  
None.  
13.7 PREGNANCY AND LIFESTYLE CONSIDERATIONS  
Contraception is not  required.  
Relative to the reporting requirements in Section 9.1.6, the following are altered: (a) P regnancies 
occurring after starting intervention activities and while on- study will be documented in the database, 
but pregnant  participants will not  be advis ed to discontinue the intervention; (b) mothers who 
conceived a child with a male participant on- study will not  be required to consent to having their 
pregnancies followed, and their pregnancies will not be followed through completion; and ( c) the DCRI 
Safety Surv eillance team will not  need to notify device supplying partners of the  pregnancy .  
Related to these alterations: Pregnancy testing is  not required at each study visit; thus, participants’ self -
report is acceptable. Additionally, pregnancy testing i s not required for female participants who self -
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
53 report menopause, have no menstrual cycle for at least 12 months, or are surgically sterile (such as 
hysterectomy, bilateral tubal ligation, bilateral oophorectomy) .  
 
 
13.8 STATISTICAL CONSIDERATIONS (APPENDIX LEVEL)  
13.8.1  SAMPLE SIZE DETERMIN ATION  
No existing published data are available to evaluate the minimal clinically meaningful effect size in the 
PASC  population. As a reference, a study of 33 patients with traumatic brain injury who were 
randomized to 5 weeks of an  intervention using similar approaches to PASC -CoRE versus 5 weeks Brain 
Health Education found improvements with effect sizes of 0.48 to 0.71 on the Mayo -Portland 
Adaptability Inventory- 4.75 
A sam ple size of 50 participants per group will provide 90% power to detect an effect size of 0.655 for a 
comparison of any two arms, using a two -sample t -test and assuming 1:1 randomization and a two -sided 
type I error rate of 0.05. Assuming 20% loss to foll ow-up, 63 participants per arm would need to be 
randomized. Table 6 provides effect sizes that can be detected with 80  and 90% power under various 
assumptions for sample size per arm a nd percent loss to follow -up. 
Table 6. Effect sizes that can be detected with 80% and 90% power under various scenarios for 
enrollment and loss to follow -up 
13.8.2  PRIMARY AND SECONDAR Y COMPARISON S 
The current interventions and design afford evaluation of the following primary comparisons:  
A. BrainHQ versus Active Comparator  
B. BrainHQ + PASC -CoRE  versus Active Comparator  
C. BrainHQ + tDCS -active versus BrainHQ + tDCS -sham  
D. BrainHQ + PASC -CoRE versus BrainHQ  
The following secondary comparisons will be evaluated:  Power  Num ber of 
patients per 
arm Number of patients 
needed per arm assuming 
10% loss to follow up  Number of patients 
needed per arm assuming 
20% loss to follow up  Effect size  
80% 50 56 63 0.57 
80% 75 83 94 0.46 
80% 100 111 125 0.40 
     
90% 50 56 63 0.66 
90% 75 83 94 0.53 
90% 100 111 125 0.46 
RECOVER -NEURO  CD_Protocol_3.0_2024_01_10 
54 E. BrainHQ + tDCS -active versus Active Comparator  
F. BrainHQ + tDCS -active versus BrainHQ  